Introduction {#s1}
============

Microtubules (MTs) are highly dynamic polarized polymers that perform critical and diverse cellular functions including formation of bipolar mitotic spindles, intracellular organization, and modulation of cell development and cell migration ([@bib2]; [@bib4]). MTs are assembled from αβ-tubulin heterodimers (herein termed αβ-tubulin), and their polymerization exhibits dynamic instability arising from guanosine triphosphate (GTP) hydrolysis in β-tubulins at MT ends. However, the conformational changes promoting soluble αβ-tubulins to polymerize at MT ends remain poorly understood. Polymerization of αβ-tubulin and GTP hydrolysis are regulated by conserved proteins that bind at MT plus-ends or along MT lattices ([@bib2]; [@bib3]; [@bib4]; [@bib8]; [@bib7]; [@bib15]). The XMAP215/Stu2/Alp14 MT polymerases are among the best-studied families of MT regulators. They localize to the extreme tips of MT plus-ends and accelerate αβ-tubulin polymerization in eukaryotes ([@bib3]; [@bib4]; [@bib8]; [@bib28]). Loss or depletion of MT polymerases is lethal in most eukaryotes as it severely decreases MT polymerization rates during interphase, resulting in shortened mitotic spindles ([@bib9]; [@bib19]; [@bib42]). MT polymerases also bind kinetochores, where they accelerate MT dynamics and regulate kinetochore-MT attachment ([@bib30]; [@bib38]). MT polymerases recruit αβ-tubulins via arrays of conserved tumor overexpressed gene (TOG) domains (herein termed TOG arrays), which are critical for their function ([@bib35]; [@bib43]). Arrays of TOG-like domains are conserved in two other classes of MT regulators, CLASP and Crescerin/CHE-12 protein families ([@bib8]; [@bib7]; [@bib20]), suggesting that arrays of TOG domains uniquely evolved to regulate diverse MT polymerization functions through the binding of αβ-tubulins in various intracellular settings.

Yeast MT polymerases, such as *Saccharomyces cerevisiae* Stu2p and *Schizosccharomyces pombe* Alp14, are homodimers containing two unique and conserved TOG domain classes, TOG1 and TOG2, per subunit, numbered based on their proximity to the N-terminus in the protein sequence. In contrast, metazoan orthologs, such as XMAP215 and ch-TOG, are monomers with five tandem TOG domains, TOG1 through TOG5 ([@bib8]; [@bib15]). Phylogenetic analyses suggest that TOG1 and TOG2 domains are evolutionarily distinct ([@bib8]), and that TOG3 and TOG4 domains in metazoans are evolutionarily and structurally exclusively related to the TOG1 and TOG2 domains, respectively ([@bib14]; [@bib22]; [@bib24]). Thus, despite differences in TOG array organization in yeast and metazoan proteins, both groups contain an array of tandem TOG1-TOG2 domains.

Structural studies contributed to our understanding of the molecular basis of TOG domain function in recruiting soluble αβ-tubulin. Each TOG domain is composed of six α-helical HEAT (Huntingtin, EF3A, ATM, and TOR) repeats, which form a conserved paddle-shaped structure ([@bib8]; [@bib6]; [@bib5]; [@bib15]; [@bib36]). X-ray structures of isolated TOG1 and TOG2 domains in complex with αβ-tubulins revealed that these domains recognize the curved αβ-tubulin conformations via inter-helical loops positioned along an edge of these paddle-shaped domains ([@bib12]; [@bib11]). Straightening of the curved αβ-tubulins upon polymerization into MTs likely dissociates TOG domains from the complexes. Our previous studies indicate that native TOG arrays from yeast or metazoan MT polymerases assemble into discrete particle-like assemblies upon binding αβ-tubulin ([@bib8]; [@bib5]). Both TOG1 and TOG2 domains are critical for MT polymerase function, and their inactivation results in MT functional defects ([@bib9]; [@bib5]; [@bib12]). Two models were proposed to explain how arrays of TOG domains function as MT polymerases. One model based on studies of native TOG arrays indicates that they may form ordered assemblies upon binding αβ-tubulins ([@bib5]; [@bib14]). A second model, based on studies of isolated TOG domains or short TOG arrays, suggests that these arrays form flexible assemblies in which TOG1 and TOG2 independently recruit multiple αβ-tubulins to MT plus-ends ([@bib8]; [@bib12]). Distinguishing between these models requires understanding the high-resolution organization of native TOG arrays in complex with αβ-tubulin and their transitions during αβ-tubulin recruitment and polymerization phases.

Here, we describe biochemical and structural states of TOG arrays during αβ-tubulin recruitment and polymerization states. We show that the yeast MT polymerase, Alp14, recruits four αβ-tubulins using dimeric arrays of TOG1-TOG2 domains. TOG1 and TOG2 domains each bind and release αβ-tubulins with different rates. X-ray structures reveal pseudo-dimeric TOG1-TOG2 subunits in head-to-tail square-shaped assemblies, each of which orients four unpolymerized αβ-tubulins in a polarized configuration. Crosslinking and mass spectrometry and electron microscopy studies show that dimeric yeast TOG arrays form these square assemblies in solution. Alp14 mutants with inactivated binding interfaces show disorganized configurations or polymerized arrangements, but without any defects in αβ-tubulin binding. Using a novel approach to promote the limited polymerization of αβ-tubulins while bound to TOG arrays, we determined an X-ray structure of an 'unfurled' TOG1-TOG2 array:αβ-tubulin assembly revealing TOG1 and TOG2 bound to two αβ-tubulins polymerized head-to-tail into a protofilament. Our studies establish a new 'polarized unfurling' model for TOG arrays as MT polymerases.

Results {#s2}
=======

TOG1 and TOG2 domains possess distinct affinities for αβ-tubulin {#s2-1}
----------------------------------------------------------------

The *S. pombe* Alp14 is a typical yeast MT polymerase, consisting of a tandem array of N-terminal TOG1 and TOG2 domains separated by a 60-residue linker, followed by a Ser-Lys-rich (SK-rich) region and a C-terminal coiled-coil domain that regulates dimerization ([Figure 1A](#fig1){ref-type="fig"}). We studied the αβ-tubulin binding capacities and stoichiometries of near native monomeric and dimeric Alp14, which both consist of TOG1-TOG2 arrays and differ by the presence of a C-terminal SK-rich region and dimerization coiled-coil domain. Using quantitative size-exclusion chromatography (SEC) with multi-angle light scattering (SEC-MALS), we measured the αβ-tubulin binding stoichiometry for monomeric Alp14 (herein termed Alp14-monomer: residues 1--510), and dimeric Alp14 (herein termed wt-Alp14-dimer: residues 1--690) at 80--100 mM KCl ionic strength ([Figure 1A--B](#fig1){ref-type="fig"}, [Figure 1D](#fig1){ref-type="fig"}; details described in [Figure 1---figure supplement 1A--C,D--F](#fig1s1){ref-type="fig"}; SEC-MALS control experiments shown in [Figure 1---figure supplement 2G--H](#fig1s2){ref-type="fig"}; [Table 1](#table1){ref-type="table"}) ([@bib9]). We show that 1 μM wt-Alp14-dimer binds four αβ-tubulins per dimer via its four TOG domains (dimeric TOG1-TOG2 arrays), whereas 1 μM wt-Alp14-monomer binds two αβ-tubulins per dimer via two TOG domains. Thus, TOG1 and TOG2 independently recruit αβ-tubulins ([Figure 1A--B,D](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1A--C,D--F](#fig1s1){ref-type="fig"}; [Tables 1](#table1){ref-type="table"} and [2](#table2){ref-type="table"}).

![TOG1 and TOG2 domains bind αβ-tubulins and exchange them at different rates, within Alp14 TOG arrays.\
(**A**) Top, domain organization of Alp14-monomer. Bottom, SEC-MALS for wt-Alp14-monomer at 100 mM KCl with and without DRP, revealing two αβ-tubulins bound in a non-polymerized state. (**B**) Top, domain organization of Alp14-dimer. Bottom, SEC-MALS for wt-Alp14-dimer in αβ-tubulin complex at 2:4 stoichiometry at 100 mM and 200 mM KCl, revealing that four αβ-tubulins bind dimeric-Alp14 with four TOG domains and two αβ-tubulins dissociate upon increase of ionic strength (masses reported in [Table 2](#table2){ref-type="table"}). (**C**) Top, organization of TOG-inactivated Alp14-dimer (C: TOG1M, TOG2M). Bottom, SEC-MALS of 4:2 TOG1M- and TOG2M-αβ-tubulin at 100 mM KCl revealing half of the αβ-tubulin binding stoichiometry compared to wt-Alp14-dimer (shown in B). (**D**) SEC-based titration measured through analyses of masses from SDS-PAGE ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}; Materials and methods) of Alp14-monomer, Alp14-dimer, and TOG1M and TOG2M with and without DRP binding, reveals the binding capacities of TOG1 and TOG2 domains in these constructs and their non-equivalence in αβ-tubulin exchange at 200 mM KCl. DRP binding to αβ-tubulin does not influence αβ-tubulin binding to TOG arrays. Details are described in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}--[2](#fig1s2){ref-type="fig"}. (**E**) Isothermal titration calorimetery (ITC) reveals TOG1 and TOG2 exchange αβ-tubulin with non-equivalent rates at 200 mM KCl. At 100 mM KCl, TOG1 and TOG2 both slowly dissociate from αβ-tubulin with K~D~ = 70 nM and K~D~ = 173 nM, respectively. At 200 mM KCl, TOG1 dissociates from αβ-tubulin slowly with a K~D~ = 1.50 μM while TOG2 mostly dissociates from αβ-tubulin with a K~D~ = 3.25 μM. ITC binding curves are shown in [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}. (**F**) Model for non-equivalent activities of TOG1 and TOG2 within TOG array for recruiting αβ-tubulins.](elife-38922-fig1){#fig1}
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###### The stoichiometry for MT polymerases TOG1-TOG2 binding αβ-tubulin and DARPin (DRP)

  ---------------------------------------------------------------------------------------------------------------
  Protein complex                              Expected Mass (kDa)   SEC-MALS Measured\   SEC\       Apparent\
                                                                     Mass\                elution\   Mass (kDa)
                                                                     (kDa)                volume\    
                                                                                          (mL)       
  -------------------------------------------- --------------------- -------------------- ---------- ------------
  αβ-Tubulin                                   100 kDa               98 ± 0.323\*         12.9       104

  Alp14-dimer                                  150 kDa               143 ± 1.70           10.0       675

  1 Alp14-dimer: 1 Tubulin 80 mM KCl           350 kDa               387 ± 2.74           9.27       463

  1 Alp14-dimer: 2 Tubulin 80 mM KCl           550 kDa               578 ± 1.41           8.98       784

  1 Alp14-dimer: 1Tubulin 200 mM KCl           350 kDa               304 ± 11.8           9.22       693

  1 Alp14-dimer: 2 Tubulin 200 mM KCl          350 kDa               392 ± 9.66           9.67       549

  1 Alp14-dimer-TOG1M: 1 Tubulin 80 mM KCl     350 kDa               400 ± 7.3            10.13      433

  1 Alp14-dimer-TOG2M: 2 Tubulin 80 mM KCl     350 kDa               382 ± 14             9.76       524

  Alp14-monomer                                62 kDa                77.8 ± 1.21          12.98      99

  1 Alp14-monomer: 2 Tubulin 80 mM KCl         262 kDa               264 ± 1.31           11.17      253

  1 Alp14-monomer: 2 Tubulin: 2 DRP 80mM KCl   298 kDa               312 ± 2.32           10.94      285

  1 Alp14-dimer-INT1: 2 Tubulin 80mM KCl       550 kDa               533 ± 3.11           8.95       775

  1 Alp14-dimer-INT2: 2 Tubulin 80mM KCl       550 kDa               580 ± 3.11           8.90       770

  1 Alp14-dimer-INT1+2: 2 Tubulin 80mM KCl     550 kDa               540 ± 3.22           8.80       790
  ---------------------------------------------------------------------------------------------------------------

\*Standard error is defined based on fitting data across peaks using Astra-software.

Since TOG1 and TOG2 domains bind αβ-tubulins via narrow and mostly ionic binding interfaces, we studied the effect of a moderate increase in ionic strength (100--200 mM KCl) on αβ-tubulin binding capacities of TOG1 and TOG2 domains in these arrays ([@bib12]; [@bib11]). At 200 mM KCl, both 1 μM wt-Alp14-monomer and wt-Alp14-dimer bound roughly half as much αβ-tubulin than at 80--100 mM KCl. Thus, either TOG1 or TOG2 domains may lose part or all of their αβ-tubulin-binding capacity at 200 mM KCl ([Figure 1B,D](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1A--C,D--F](#fig1s1){ref-type="fig"} and [Tables 1](#table1){ref-type="table"} and [2](#table2){ref-type="table"}). These differences between the αβ-tubulin-binding stoichiometries at 100 versus 200 mM KCl resolve discrepancies regarding Alp14- or Stu2-αβ-tubulin-binding stoichiometries reported previously ([@bib12]; [@bib9]; [@bib5]).

We next determined if the αβ-tubulin-binding capacity of TOG1 or TOG2 changed within arrays due to a change in ionic strength from 100 to 200 mM KCl. Using SEC and SEC-MALs, we studied the αβ-tubulin-binding stoichiometry for Alp14-dimer mutants in which either TOG1 (termed TOG1M) or TOG2 (termed TOG2M) were inactivated through multiple-residue mutations in the αβ-tubulin-binding interfaces ([@bib6]; [@bib11]); see Materials and methods; [Figure 1C](#fig1){ref-type="fig"}, [Figure 1D](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1G--L](#fig1s1){ref-type="fig"}). 1 μM TOG1M, which only includes two active TOG2 domains, bound two αβ-tubulins at 100 mM KCl, but almost completely dissociated from αβ-tubulin at 200 mM KCl. TOG1M and αβ-tubulin did not co-migrate on SEC, and most of the αβ-tubulin migrated as a separate peak at 200 mM KCl ([Figure 1D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1G--I](#fig1s1){ref-type="fig"}; [Tables 1](#table1){ref-type="table"} and [2](#table2){ref-type="table"}). In contrast, TOG2M, which only includes two active TOG1 domains, bound and co-migrated with αβ-tubulin in both 100 and 200 mM KCl conditions ([Figure 1D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1J--L](#fig1s1){ref-type="fig"}, [Tables 1](#table1){ref-type="table"} and [2](#table2){ref-type="table"}). Moreover, molar ratios of αβ-tubulin bound to TOG1M and TOG2M measured by quantitative-SEC at 100 mM KCl and maximal αβ-tubulin stoichiometry determined by SEC-MALS at 80 mM KCl were roughly half of that measured for wt-Alp14-dimer at 80--100 mM KCl ([Figure 1C,D](#fig1){ref-type="fig"}). These data support the independent and distinct affinities of TOG1 and TOG2 domains in recruiting αβ-tubulins while within either monomeric or dimeric arrays, and that dimerization does not change the αβ-tubulin-binding stoichiometry. TOG1 and TOG2 showed distinct αβ-tubulin binding behaviors at 100 and 200 mM KCl ([Figure 1F](#fig1){ref-type="fig"}; the SEC-MALS controls are shown in [Figure 1---figure supplement 2G](#fig1s2){ref-type="fig"})

Next, we quantitatively measured the absolute TOG1 and TOG2 binding affinities for αβ-tubulin using isothermal titration calorimetery (ITC), and determined how these affinities were influenced by changes in ionic strength at 100--200 mM KCl. ITC data showed that isolated TOG1 (residues 1--270) and TOG2 (residues 320--510) bound αβ-tubulins with roughly 2.5-fold difference in dissociation constants ([Figure 1E](#fig1){ref-type="fig"}; [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). At 100 mM KCl, the dissociation constants for TOG1 and TOG2 were measured at 70 and 173 nM, respectively. These data suggest that both TOG1 and TOG2 exhibit a moderately high affinity for αβ-tubulin with a 2.5-fold difference in affinity, nearly identical to that previously reported ([@bib12]; [@bib11]). However, at 200 mM KCl, we measured TOG1 and TOG2 αβ-tubulin dissociation constants at 1.5 μM and 3.2 μM, respectively, which showed 20-fold weaker affinity in absolute values compared to those measured at 100 mM KCl. Together, our studies suggest that within the cellular αβ-tubulin concentration range (5--10 μM) and 1 μM Alp14 at 100 mM KCl or below, each TOG1-TOG2 subunit tightly binds two αβ-tubulins, whereas at 200 mM KCl, each TOG1-TOG2 subunit binds one αβ-tubulin tightly via TOG1 and exchanges a second αβ-tubulin rapidly via TOG2. In conditions of 200 mM KCl, 1 μM Alp14, and 5--10 μM αβ-tubulin, TOG1 domains is almost completely occupied by αβ-tubulin, while TOG2 domains is mostly dissociated from αβ-tubulin ([Figure 1F](#fig1){ref-type="fig"}).

X-ray structures of a recruitment complex: pseudo-dimeric TOG1-TOG2 arrays in a head-to-tail square assembly that pre-orients αβ-tubulins {#s2-2}
-----------------------------------------------------------------------------------------------------------------------------------------

Our biochemical analyses suggest that structural studies of TOG array:αβ-tubulin complexes must be conducted at lower ionic strengths of 80--100 mM KCl and at high αβ-tubulin concentrations to avoid αβ-tubulin dissociation from TOG2 domains. To further increase TOG1-TOG2:αβ-tubulin complex formation and inhibit αβ-tubulin self-assembly under such conditions, we utilized the designed ankyrin repeat protein (DARPin) D1 (herein termed DRP), which specifically binds and neutralizes the β-tubulin polymerizing interface ([@bib32]). First, we studied if DRP binding to αβ-tubulin influenced wt-Alp14-monomer or wt-Alp14-dimer binding stoichiometries to multiple αβ-tubulins. We measured binding molar ratios using quantitative-SEC and stoichiometry using SEC-MALs for DRP-bound-αβ-tubulin to wt-Alp14-dimer and wt-Alp14-monomer in 80--100 mM KCl conditions, respectively ([Figure 1A](#fig1){ref-type="fig"}; [Figure 1---figure supplement 2A--F](#fig1s2){ref-type="fig"}; [Tables 1](#table1){ref-type="table"} and [2](#table2){ref-type="table"}). We showed that DRP did not affect the simultaneous binding of multiple αβ-tubulins to TOG1-TOG2 arrays in either wt-Alp14-monomer or wt-Alp14-dimer. 1 μM wt-Alp14-dimer formed a complex with four αβ-tubulins and four DRPs at a molar ratio of 2:4:4 ([Figure 1D](#fig1){ref-type="fig"}; [Figure 1---figure supplement 2D--F](#fig1s2){ref-type="fig"}). We measured a mass of the wt-Alp14-monomer:αβ-tubulin:DRP complex by SEC-MALS that indicated a 1:2:2 stoichiometry complex in which each TOG1-TOG2 subunit bound two αβ-tubulins, each of which bound its own DRP ([Figure 1A,D](#fig1){ref-type="fig"}; [Figure 1---figure supplement 2A--C,G](#fig1s2){ref-type="fig"}; [Table 2](#table2){ref-type="table"}). The ability of Alp14-bound αβ-tubulin to bind stoichiometric amounts of DRP suggests that αβ-tubulins recruited by TOG arrays are in a non-polymerized state upon initial association with Alp14. This feature is consistent with a reported lack of cooperativity described between TOG1 and TOG2 in binding to αβ-tubulins ([@bib12]). Thus, we used this strategy to identify crystallization conditions using TOG array orthologs from a variety of organisms (see Materials and methods).

Crystals of the *Saccharomyces kluyveri* ortholog of Alp14 (herein termed sk-Alp14-monomer: residues 1--550) bound to αβ-tubulins and DRP grew in conditions similar to those used for SEC and SEC-MALS ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Using crystals with either a native sk-Alp14-monomer or an sk-Alp14-monomer with a modified TOG1-TOG2 linker sequence (termed sk-Alp14-monomer-SL; see Materials and methods; [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}), we determined X-ray structures for 1:2:2 TOG1-TOG2 array:αβ-tubulin:DRP from complexes using sk-Alp14-monomer and sk-Alp14-monomer-SL using molecular replacement (see Materials and methods) at 4.4 Å and 3.6 Å resolution, respectively ([Table 3](#table3){ref-type="table"} and [Figure 2---figure supplement 1B,C](#fig2s1){ref-type="fig"}). In the structures, TOG1 domains were clearly differentiated from TOG2 domains by their conserved C-terminal extension and jutting α-helix that were unambiguously identified in density-modified maps ([Figure 2---figure supplement 1D,E](#fig2s1){ref-type="fig"}). Each asymmetric unit contained two wheel-shaped assemblies ([Figure 2---figure supplement 1F](#fig2s1){ref-type="fig"}) representing two sets of alternating TOG1 and TOG2 domains oriented in a square-like conformation (termed the TOG square), with each TOG domain binding a DRP-capped αβ-tubulin on its outer edge. Excluding the 10-residue TOG1-TOG2 linker region immediately preceding TOG2, the remaining 40 residues of the linker were disordered ([Figure 2---figure supplement 1F--I](#fig2s1){ref-type="fig"}).

The dimension of each wheel-like assembly was 210 × 198 × 60 Å ([Figure 2A](#fig2){ref-type="fig"}). The 2:4:4 stoichiometry observed in the X-ray structure matched the stoichiometry measured for wt-Alp14-dimer:αβ-tubulin:DRP complexes ([Figure 1D](#fig1){ref-type="fig"}; [Figure 1---figure supplement 2D--F](#fig1s2){ref-type="fig"}). We hypothesized that sk-Alp14-monomer formed dimeric organization, despite the lack of dimerization domains, due to the high concentration of these complexes during crystallization. X-ray structures revealed two TOG1-TOG2 subunits in a pseudo-dimeric assembly forming the core of these complexes. In a TOG square, each TOG domain was bound to a curved αβ-tubulin capped by a DRP through its outward-facing binding interface and was not in contact with the neighboring TOG-bound αβ-tubulin ([Figure 2A](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1F--H](#fig2s1){ref-type="fig"}). The distances and interaction patterns between residues of α-tubulin and DRP bound to a neighboring β-tubulin indicated that DRP only interacts with its cognate β-tubulin and does not bind a neighboring α-tubulin ([Figure 2---figure supplement 1J,K](#fig2s1){ref-type="fig"}). The latter suggests that DRP has no effect on stabilizing each TOG square assembly. Rather, DRP binding only caps β-tubulin, presenting a significant impediment to the polymerization of αβ-tubulins while bound to the TOG1-TOG2 subunits. The αβ-tubulins bound to the TOG square are positioned in a polarized orientation, due to the asymmetry in the TOG domain αβ-tubulin interface and pseudo-dimeric TOG1-TOG2 subunit interfaces within the TOG square (see below). The β-tubulin on a TOG1-bound αβ-tubulin is rotated approximately 90° from its polymer-forming interface relative to the adjacent α-tubulin on a TOG2-bound αβ-tubulin ([Figure 2B](#fig2){ref-type="fig"}).

![X-ray structures reveal αβ-tubulins bound in a wheel-like organization around a pseudo-dimeric TOG square complex.\
(**A--B**) 3.6 Å X-ray crystal structure of the *S. kluyveri* 1:2:2 sk-Alp14:αβ-tubulin:DRP reveals pseudo-dimeric head-to-tail subunits (red and orange) in a TOG square assembly consisting of four TOG domains bound to four αβ-tubulins (α-tubulin shown in cyan and β-tubulin shown in green) in a wheel-like organization. (**A**) Structure with DRP (yellow) bound to each αβ-tubulin. (**B**) Structure with DRP computationally removed. Each αβ-tubulin (α1β1) is positioned 90° rotated from its polymer-forming interface on its neighboring αβ-tubulin (α2β2). (**C**) Pseudo-dimeric TOG1-TOG2 subunits, shown in orange and red, respectively, form a head-to-tail TOG square (inset). Interface 1 is formed by the N-terminus of TOG2 and the TOG1-TOG2 linker binding to the C-terminus of the TOG1 domain of a second subunit, forming a 90° corner. Interface 2 is formed by the N-terminus of TOG1 binding the C-terminus of TOG2 within the same subunit in a 90° corner ([Figure 2---figure supplement 1I](#fig2s1){ref-type="fig"}). (**D**) Rainbow view of TOG1-TOG2 with N- and C-termini displayed in a blue-to-red color gradient, while the other subunit is displayed in grey. Each TOG is composed of six HEAT repeats (numbered). (**E**) Close-up view of interface 1. A hydrophobic zone stabilizes interface1 (yellow and highlighted by red outline) involving Leu220 (L220) and Leu217 (L217) of the TOG1 inter-HEAT 5--6 loop, Leu179 (L179) of the HEAT 6 A-helix in TOG1 (red ribbon) stabilized by linker residues (solid orange) Phe302 (F302), Leu304 (L304), and Leu305 (L305). An ionic zone guides interface 1 involving Glu219 (E219) of TOG1 inter-HEAT 5--6 loop and Glu305 (E305) of the TOG1-TOG2 linker, forming salt bridges with Lys346 (K346) and Lys347 (K347) of the TOG2 (light orange) inter-HEAT 1--2 loop and Arg390 (R390) of the TOG2 HEAT 2,3 loop, respectively. (**F**) Close-up view of interface 1, as in C, displaying residue conservation based on the alignment shown in [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}. (**G**) Close-up view of interface 2. A hydrophobic zone stabilizes interface 1 involving Leu477 (L477) and Leu472 (L472) of the TOG2 inter-HEAT4-5 loop with Ile43 of the TOG1 inter-HEAT1-2 loop. Ionic zone selectively guides interface 2, involving Lys39 (K39) and Ser41 (S41) of the TOG1 inter-HEAT1-2 loop and helix 1B with Arg517 (R517), Glu518 (E518), Asp521 (D521), and Glu524 (E524) of the TOG2 inter-HEAT5-6 loop and A-helix. (**H**) Close-up view of interface 2, as in D, displaying reside conservation based on the alignment in [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}.](elife-38922-fig2){#fig2}
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###### Capacities of MT polymerase TOG1-TOG2 to bind αβ-tubulin, influenced by ionic strength

  ------------------------------------------------------------------------------------------
  Protein Complex\                          µM tubulin\* bound   µM tubulin\   TOG1-TOG2\
  (Alp14-monomer concentration 4.43 uM)                          free          :αβ-tubulin
  ----------------------------------------- -------------------- ------------- -------------
  **wt-Alp14-monomer (2 µM)**                                                  

  1 Alp14-monomer: 1 Tub 100 mM KCl         4.57 ± 0.08          0.43 ± 0.08   1.04

  1 Alp14-monomer: 2 Tub 100 mM KCl         8.82 ± 0.16          1.18 ± 0.16   2

  1 Alp14-monomer: 1 Tub 200 mM KCl         3.37 ± 0.27          1.63 ± 0.27   0.76

  1 Alp14-monomer: 2 Tub 200 mM KCl         5.97 ± 0.12          4.03 ± 0.12   1.35

  1 Alp14-monomer:1 Tub:1 DRP 100 mM KCl    4.33 ± 0.13          0.67 ± 0.13   0.98

  1 Alp14-monomer:2 Tub:2 DRP 100 mM KCl    7.23 ± 0.01          2.77 ± 0.01   1.64

  1 Alp14-monomer:1 Tub:1 DRP 200 mM KCl    4.13 ± 0.09          0.87 ± 0.09   0.94

  1 Alp14-monomer: 2 Tub 2 DRP 200 mM KCl   5.67 ± 0.03          4.34 ± 0.03   1.28

  **wt-Alp14-dimer (1 µM)**                                                    

  1 Alp14-dimer: 1 Tub 100 mM KCl           4.31 ± 0.07          0.69 ± 0.07   0.98

  1 Alp14-dimer: 2 Tub 100 mM KCl           7.11 ± 0.14          2.89 ± 0.14   1.61

  1 Alp14-dimer: 1 Tub 200 mM KCl           3.44 ± 0.37          1.56 ± 0.37   0.78

  1 Alp14-dimer: 2 Tub 200 mM KCl           5.46 ± 0.34          4.55 ± 0.34   1.24

  1 Alp14-dimer: 1 Tub: 2 DRP 100 mM KCl    4.23 ± 0.02          0.78 ± 0.02   0.96

  1 Alp14-dimer: 1 Tub: 2 DRP 100 mM KCl    8.33 ± 0.09          1.67 ± 0.09   1.89

  1 Alp14-dimer: 1 Tub: 1 DRP 200 mM KCl    4.17 ± 0.29          0.83 ± 0.29   0.95

  1 Alp14-dimer: 2 Tub: 2 DRP 200 mM KCl    6.02 ± 0.17          3.99 ± 0.17   1.36

  **TOG square Interface mutants (1 µM)**                                      

  1 INT1: 2 Tub 100mM KCl                   8.34 ± 0.07          1.66 ± 0.07   1.74

  1 INT1: 2 Tub 200mM KCl                   5.67 ± 0.04          4.33 ± 0.04   1.18

  1 INT2: 2 Tub 100mM KCl                   9.52 ± 0.3           0.48 ± 0.2    2.02

  1 INT2: 2 Tub 200mM KCl                   6.82 ± 0.2           3.1 ±0.1      1.45

  1 INT1+2: 2 Tub 100mM KCl                 8.44 ± 0.05          1.56 ± 0.05   1.86

  1 INT1+2: 2 Tub 200mM KCl                 6.85 ± 0.04          3.15 ± 0.04   1.46

  **Inactivated TOG mutants (1 µM)**                                           

  1 TOG1M: 1 Tub 100 mM KCl                 4.04 ± 0.07          0.97 ± 0.07   0.92

  1 TOG1M: 2 Tub 100 mM KCl                 4.94 ± 0.06          5.06 ± 0.06   1.12

  1 TOG1M: 1 Tub 200 mM KCl                 1.66 ± 0.25          3.34 ± 0.25   0.38

  1 TOG1M: 2 Tub 200 mM KCl                 2.23 ± 0.1           7.77 ± 0.1    0.51

  1 TOG2M: 1 Tub 100 mM KCl                 3.53 ± 0.04          1.48 ± 0.04   0.8

  1 TOG2M: 2 Tub 100 mM KCl                 6.24 ± 0.10          3.76 ± 0.1    1.41

  1 TOG2M: 1 Tub 200 mM KCl                 3.15 ± 0.24          1.85 ± 0.24   0.72

  1 TOG2M: 2 Tub 200 mM KCl                 4.28 ± 0.18          5.72 ± 0.18   0.97
  ------------------------------------------------------------------------------------------

\*Standard error is defined based on combined data from duplicated SEC runs.

Two interfaces stabilize TOG1-TOG2 subunits into a TOG square assembly {#s2-3}
----------------------------------------------------------------------

The X-ray structures revealed that each TOG square is a dimer of TOG1-TOG2 array subunits assembled head-to-tail from alternating TOG1 and TOG2 domains. TOG domains were aligned along their narrow edges, analogous to four links attached head-to-tail forming an asymmetric square-like complex with two edges slightly longer than their orthogonal edges ([Figure 2C,D](#fig2){ref-type="fig"}). Two contact sites, which we term interfaces 1 and 2, stabilize the TOG square. These interfaces are formed by interactions formed via inter-HEAT repeat loops of each TOG domain, which are located on the opposite edges from the αβ-tubulin-binding sites. Although TOG1 and TOG2 domains are each 60 Å long, the TOG square assembly is slightly rectangular with 115 Å by 98 Å dimensions due to wider overlaps between TOG1 and TOG2 domains leading to 10 Å stagger at interface 1 sites, in contrast to the direct end-on corner-like interface 2 sites. Both interfaces 1 and 2 are stabilized by hydrophobic packing and ionic interaction zones ([Figure 2E--H](#fig2){ref-type="fig"}). Interface 1 packs a 668 Å^2^ surface area and positions the TOG1 C-terminus at 90° to a 10-residue segment of the TOG1-TOG2 linker and the N-terminus of TOG2. The TOG1-TOG2 linker sequence forms an extended polypeptide that critically bridges interactions between TOG1 inter-HEAT repeat 6 α-helix/inter-HEAT 5--6 loop segment and the TOG2 inter-HEAT repeat 1-2/2-3 loop segments ([Figure 2E,F](#fig2){ref-type="fig"}). Interface 2 packs a 290 Å^2^ surface area and positions the TOG2 C-terminus at 90° to the N-terminus of TOG1 ([Figure 2G,H](#fig2){ref-type="fig"}). In interface 2, the TOG2 inter-HEAT repeat 4--5 loop interacts with the TOG1 inter-HEAT repeat 1--2/HEAT1 α-helix ([Figure 2G](#fig2){ref-type="fig"}). The residues forming interface 1 and interface 2 within TOG1, TOG2, and linker regions are either moderately or highly conserved ([Figure 2F,H](#fig2){ref-type="fig"}; [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). The total buried surface area stabilizing two sets of interfaces 1 and 2 in a TOG square is 1930 Å^2^, which is moderate in size and dispersed for such a large assembly. This finding suggests that this conformation may be meta-stable and that DRP binding and its inhibition of αβ-tubulin polymerization may stabilize this intermediate.

Cysteine crosslinking and mass spectrometry reveal Alp14-dimer forms TOG square assembly interfaces in solution {#s2-4}
---------------------------------------------------------------------------------------------------------------

Next, we examined and chemically trapped the direct physical interactions between TOG1 and TOG2 interfaces observed in TOG square structures using cysteine mutagenesis and disulfide crosslinking. We generated mutants with specific cysteine pairs within the two sides of interface 1 (S180C, L304C) or interface 2 (S41C, E518C) in native dimeric sk-Alp14 (termed sk-Alp14-dimer; residues 1--724) ([Figure 3A,B](#fig3){ref-type="fig"}). We tested whether these interfaces formed inter-subunit contacts in dimeric TOG array by crosslinking via disulfide oxidation. A 110 kDa crosslinked species was observed in all conditions where soluble αβ-tubulin was added, and mass spectrometry (LC/MS-MS) confirmed that this intermediate was indeed a crosslinked α- and β-tubulin heterodimer ([Figure 3C,D](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). We also observed a \~ 170 kDa species that specifically formed in the αβ-tubulin-bound sk-Alp14 S180C-L304C mutant and not in the native sk-Alp14-dimer or the sk-Alp14-S41C-E518C mutants. Furthermore, this 170 kDa intermediate was also not observed with sk-Alp14-S180C-L304C without αβ-tubulin ([Figure 3D](#fig3){ref-type="fig"}). Mass spectrometry confirmed that this 170 kDa intermediate was indeed the sk-Alp14-S180C-L304C protein. Next, we mapped the cysteine residues involved in disulfide bonds in sk-Alp14-S180C-L304C mutants through peptide disulfide mapping after differential alkylation and mass spectrometry (see Materials and methods). This approach revealed only two classes of peptides in sk-Alp14-S180C-L304C with 105 Da of mass added onto the cysteines, suggesting that they were engaged in disulfide bonds with the following sequence boundaries: 297--320 and 179--189 ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). These two peptide sequences represent TOG1 inter-HEAT-repeat and TOG1-TOG2 linker regions, both of which are involved in forming interface 1 in the X-ray structures ([Figure 2](#fig2){ref-type="fig"}). All the remaining peptides with cysteine residues that were identified in sk-Alp14-S180C-L304C included 57 Da in added mass, suggesting that they were in the reduced form and did not form disulfide bridges. Thus, these data directly provide independent support of interface 1 of the TOG square conformation forming in sk-Alp14-dimer in solution outside of the crystallographic setting, and of indeed being the inter-subunit dimeric interface between two TOG-array subunits, as visualized in the crystal structures ([Figure 3A,B](#fig3){ref-type="fig"}).

![Cysteine mutagenesis/crosslinking and mass spectrometry-based peptide-mapping reveal that dimeric sk-Alp14 forms TOG square conformations in solution.\
(**A**) TOG square structure showing two cysteine pairs (green space fill) mutated in interfaces 1 (black-dashed lines) and 2 (red-dashed lines). (**B**) Close-up views of interfaces 1 (left) and 2 (right) showing the S180C-L304C and E518C-S41C residue pairs, respectively (green space fill), in sk-Alp14. (**C**) SDS-PAGE of SEC-purified sk-Alp14 S180C-L304C and E518C-S41C. (**D**) Crosslinking studies of cysteine structural-based mutants using oxidizing conditions and αβ-tubulin binding, as denoted by (+) and (--). The αβ-tubulins form an intermediate in oxidizing conditions observed in all conditions that include αβ-tubulin (marked '\*'). S180C-L304C sk-Alp14 forms a dimeric 170 kDa intermediate upon oxidization and αβ-tubulin binding (red arrow). In contrast, wt-Alp14 or sk-Alp14 E518C-S41C do not form this intermediate. (**E**) Disulfide peptide mapping of cysteines in sk-Alp14 S180C-L304C using differential alkylation and LC/MS-MS. We used mass spectrometry (LC/MS-MS) after a differential alkylation strategy ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}) to map peptides with disulfides. Briefly, oxidized sk-Alp14 S180C-L304C (170 kDa) SDS-PAGE-purified bands were subjected to proteolysis and treated with iodoacetamide. Under these conditions, 57 Da in mass is added to peptides with reduced cysteines (free thiols), without affecting disulfides. Dithiothreitol was then used to reduce peptides with disulfides, which were then treated with 4-vinyl pyridine, which added 105 Da in mass to peptides with newly formed free thiols. Using LC/MS-MS, peptides with modified cysteines were identified based on added mass. Details provided in [Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}.](elife-38922-fig3){#fig3}

10.7554/eLife.38922.013

###### X-ray Crystallographic and Refinement statistics of MT polymerase:αβ-tubulin:DRP.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Data collection                        1:2:2 sk-Alp14-monomer:\          1:2:2 sk-Alp14-monomer-SL:\      1:2:2 sk-Alp14-monomer:\         1:2:2 sk-Alp14-dimer:\
                                         αβ-Tubulin:DRP                    αβ-Tubulin:DRP                   αβ-Tubulin:DRPΔN                 αβ-Tubulin:DRPΔN
  -------------------------------------- --------------------------------- -------------------------------- -------------------------------- -------------------------------
  Resolution range (Å)                   96.59 - 4.40 (4.64- 4.40)^*\**^   59.45 -- 3.60 (3.79 -- 3.60)\*   57.56 -- 3.20 (3.37 -- 3.20)\*   99.83 -- 3.5 (3.69 -- 3.50)\*

  Space group                            *P* 2~1~                          *P* 2~1~                         *P* 2~1~                         *P* 2~1~

  Wavelength (Å)                         0.9792                            0.9792                           0.9792                           0.9792

  Unit cell (Å): *a*, *b*, *c*\          218.80, 107.65, 282.74\           218.48, 106.15, 282.23\          115.13, 194.99, 149.57\          122.73 199.67, 162.70\
  (°): β                                 90.38                             90.39                            90.19                            90.09

  Total number of observed reflections   229567                            380856                           298551                           235576

  Unique reflections                     80099 {68039}^†^                  142673 {121943}^†^               104265 {88337}^*†*^              91368

  Average mosaicity                      0.57                              0.38                             0.64                             0.50

  Multiplicity                           2.9 (2.9)^*\**^                   2.7 (2.7)^*\**^                  2.9 (2.9)^*\**^                  2.6 (2.4)^*\**^

  Completeness (%)                       95.4 (94.8) {80.6}^†^             95.0 (96.7) {79.0}^†^            96.2 (97.9) {82.0}^†^            92.9 (90.2)^*\**^

  Wilson B-factor (Å^2^)                 82.7                              81.4                             46.6                             \-

  \<*I*/*σ* (*I*)\>                      4.9 (1.9)^*\**^                   4.8 (1.2)^*\**^                  5.8 (1.5)^*\**^                  4.8 (1.1)^*\**^

  *R*~merge~^*c*^                        0.14 (0.48)^*\**^                 0.13(0.65)^*\**^                 0.13(0.65)^*\**^                 0.14 (0.63)^*\**^

  **Structure refinement**                                                                                                                   

  *R*~work~                              0.23 (0.26)*\**                   0.20 (0.24)*\**                  0.18 (0.23)*\**                  \-

  *R*~free~                              0.26 (0.33)*\**                   0.24 (0.26)*\**                  0.24 (0.26)*\**                  \-

  Complexes per asymmetric unit          2                                 2                                2                                \-

  Number of atoms                        78030                             77878                            36865                            \-

  Protein residues                       9989                              9981                             4661                             \-

  Ligand atoms                           496                               496                              248                              \-

  RMS bond lengths (Å)                   0.004                             0.004                            0.004                            \-

  RMS bond angles (°)                    0.94                              0.98                             0.93                             \-

  Ramachandran favored (%)               94.0                              94.0                             95.0                             \-

  Ramachandran allowed (%)               5.4                               5.5                              4.5                              

  Ramachandran outliers (%)              0.3                               0.3                              0.2                              \-

  Clashscore                             4.5                               4.8                              5.6                              \-

  Mean *B* values (Å^2^)                                                                                                                     

  Overall                                108.4                             98.3                             48.6                             \-

  Macromolecules                         108.6                             98.4                             48.6                             \-

  Ligands                                78.5                              91.5                             36.4                             \-
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Numbers represent the highest-resolution shell.

†Numbers represent the truncated data after treated with ellipsoidal truncation and anisotropic scaling.

^*‡*^*R*~merge~ = Σ~*hkl*~Σ~*i*~\|*I*~*i*~(*hkl*)-*I*~*av*~(*hkl*)\|/Σ~*hkl*~Σ~*i*~*I*~*i*~(*hkl*).

Disrupting TOG square assembly interfaces destabilizes organization, but does not affect αβ-tubulin binding {#s2-5}
-----------------------------------------------------------------------------------------------------------

We explored the role of interfaces 1 and 2 in stabilizing TOG square assembly and their effect on the αβ-tubulin capacity of TOG arrays. We generated three Alp14-dimer mutants that harbored either partially or fully disrupted interface 1 and 2 sites ([Figure 4A--D](#fig4){ref-type="fig"}). We targeted disruption of salt bridges or hydrophobic zones in interfaces 1 and 2 by mutating conserved alanines, leucines, or glutamates ([Figure 2E,G](#fig2){ref-type="fig"}; [Figure 4A--D](#fig4){ref-type="fig"}). Charged residues were either replaced with alanines or residues of the opposite charge, and hydrophobic residues were replaced with charged residues to dissociate hydrophobic interactions ([Figure 4A--D](#fig4){ref-type="fig"}). Initially, we disrupted interfaces 1 and 2 using one-, two-, or three-residue mutations in wt-Alp14-dimer. However, these mutants showed substantial levels of TOG square assemblies as assessed by negative stain electron microscopy (EM) (data not shown). Thus, we aimed to fully disrupt interfaces 1 and 2 by using seven to eight residues per interface. We mutated 8 residues in wt-Alp14-dimer to disrupt interface 1 (termed INT1; [Figure 4B](#fig4){ref-type="fig"}), 7 residues in wt-Alp14-dimer to disrupt interface 2 (termed INT2; [Figure 4C](#fig4){ref-type="fig"}), or 15 residues to disrupt both interfaces 1 and 2 (termed INT1 +2; [Figure 4D](#fig4){ref-type="fig"}) (see Materials and methods).

![Inactivation of interfaces 1 and 2 destabilizes TOG square organization without affecting αβ-tubulin binding.\
(**A--D**) Generation of structure-based TOG square assembly-defective mutants using wt-Alp14-dimer (**A**) through inactivation of interface 1 in the INT1 mutant (B: INT1, pink; eight mutant residues), interface 2 in the INT2 mutant (C: INT2, green; seven mutant residues), or both interfaces 1 and 2 in the INT1 +2 mutant (D: INT1 +2, grey; 15 mutant residues). (**E**) Summary of SEC-measured αβ-tubulin-binding molar ratios of INT1, INT2, and INT1 +2 compared to wt-Alp14-dimer as described for [Figure 1D](#fig1){ref-type="fig"} suggests no defects in αβ-tubulin binding at 100 mM KCl (blue) and a similar decrease in αβ-tubulin binding upon 200 mM KCl ionic strength increase (cyan). Additional information is described in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}. (**F--H**) SEC-MALS of INT1:αβ-tubulin (**F**), INT2:αβ-tubulin (**G**), and INT1 +2: αβ-tubulin (**H**) complexes at 2:4 stoichiometry at 100 mM KCl (masses reported in [Table 1](#table1){ref-type="table"}). SEC-MALS reveals similar mass to wt-Alp14-dimer complexes with αβ-tubulin which are reported [Table 2](#table2){ref-type="table"}. (**I**) Top, raw negative stain EM image of wt-Alp14-dimer:αβ-tubulin at 100 mM KCl reveals wheel-shaped assemblies that are 15--19 nm in diameter as previously described for Stu2-αβ-tubulin complexes ([@bib5]). Middle panel, 2D-classes reveal 19 nm wheel-shaped particles that match the 2D-projection of 30 Å resolution-filtered 2:4 TOG-square:αβ-tubulin complex (shown above the panel). These classes match the organization observed in the structure described in [Figure 2](#fig2){ref-type="fig"}. Bottom panel, second group of 2D-classes reveal small diamond-shaped particles that match the 2D-projection of a 30 Å resolution-filtered model of the TOG square without αβ-tubulins (shown above the panel). (**J**) raw image of INT1:αβ-tubulin reveals elongated conformations with either bent-conformations composed of bent-particles with two 8 nm densities at 90-degree angles or 16 nm filament-like particles. Middle panel, 2D-classes reveal 16 nm elongated classes that match the 2D-projection of either 30 Å resolution-filtered TOG1-TOG2 bound to two polymerized tubulins (shown above the second row) as described structurally in the next section. Left panel, 90-degree bend class averages that match 2D-projections of a resolution-filtered model of one TOG1-TOG2 subunit of the TOG square bound to two tubulins at 90 degrees (as shown above). Bottom panel, 2D-classes reveal 8 nm lengths, which match 2D-projections of low-resolution-filtered TOG-αβ-tubulin complexes (PDB ID: 4FFB shown above the panel). (**K**) INT2 forms extended necklace shaped or extended 16 nm minifilaments. Middle panel, 2D-class averages reveal either 16 nm filament-like particles match 2D-projections of TOG1-TOG2 bound to two polymerized αβ-tubulins (left) or bent particles that match 2D-projections of a bend TOG1-TOG2 subunit bound to two non-polymerized αβ-tubulins, as observed in half a TOG square complex (right). (**L**) INT1 +2:αβ-tubulin complexes form only dissociated assemblies with randomly interconnected 8 nm assemblies. Bottom panel, 2D-classes reveal 8 nm lengths, which match 2D-projections of low-resolution-filtered TOG-αβ-tubulin complexes (PDB ID:4FFB shown above the panel). Additional information can be found in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}.](elife-38922-fig4){#fig4}
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###### Buried Surface Area between αβ-tubulin dimer and TOG domains or DRP.

  --------------------------------------------------------------------------------------------------------------------
  Interface                     1:2:2: sk-Alp14-monomer:\   1:2:2: sk-Alp14-monomer-SL:\   1:2:1: sk-Alp14-monomer:\
                                αβ-Tubulin: DRP(Å^2^)\*     αβ-Tubulin: DRP (Å^2^)         αβ-Tubulin: DRP-ΔN (Å^2^)
  ----------------------------- --------------------------- ------------------------------ ---------------------------
  TOG1 and TOG2-interface 2     273 ± 35                    257 ± 42                       \-

  TOG1-TOG2 dimer-interface 1   661 ± 27                    702 ± 18                       \-

  αβ-tubulin and TOG1           752 ± 12                    786 ± 42                       804 ± 24

  αβ-tubulin and TOG2           916 ± 23                    890 ± 22                       863 ± 12

  β-tubulin and DRP or DRP-ΔN   842 ± 68                    873 ± 21                       846 ± 20

  α-tubulin and DRP\            108 ± 47                    81 ± 31                        \-
  (inter-αβ-tubulin subunit)                                                               
  --------------------------------------------------------------------------------------------------------------------

\*Interface areas were determined by a single buried surface, and averaged among each non-crystallographic unit in the structure.

We studied the αβ-tubulin-binding capacities and stoichiometries of INT1, INT2, and INT1 +2 compared to wt-Alp14-dimer using quantitative-SEC and SEC-MALS approaches, respectively, as described in [Figure 1](#fig1){ref-type="fig"}. INT1, INT2, and INT1 +2 mutants bound nearly identical quantities of αβ-tubulin to wt-Alp14-dimer ([Figure 4E](#fig4){ref-type="fig"}; [Figure 4F,G,H](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). INT1, INT2, and INT1 +2 bound approximately four αβ-tubulins at 80 mM KCl as assessed by SEC-MALS ([Tables 1](#table1){ref-type="table"} and [2](#table2){ref-type="table"}; [Figure 4F,G,H](#fig4){ref-type="fig"}) and approximately half of the bound αβ-tubulin dissociated at 200 mM KCl as quantitated by quantitative-SEC ([Figure 4D](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1D,E,F](#fig4s1){ref-type="fig"}).

We next used negative stain EM and 2D-single particle image analyses to compare the conformations of four αβ-tubulin-bound wt-Alp14-dimer assemblies to the αβ-tubulin:INT1, INT2 and INT1 +2 mutant assemblies. Negative stain images showed that 4:2 wt-Alp14-dimer:αβ-tubulin complexes formed two types compact particle-like assemblies of either 15 or 19 nm diameter compact circular complexes ([Figure 2](#fig2){ref-type="fig"}) matched the general features previously described for yeast Stu2p-tubulin or XMAP215-tubulin we previously described ([@bib5]; [@bib14]). 2D-image class averages were compared via projection-matching to low resolution-filtered structural models for a TOG square with and without four αβ-tubulins, revealing TOG square bound to four αβ-tubulins matched well the density organization of the 19 nm diameter 2D-class averages ([Figure 4I](#fig4){ref-type="fig"}; [Figure 4---figure supplement 2B](#fig4s2){ref-type="fig"}). 2D-projections of a low-resolution filtered TOG square model without αβ-tubulins bound matched well the organization of the 15 nm diameter class averages suggesting those classes represent TOG squares that likely lost their bound αβ-tubulins on the grid ([Figure 4I](#fig4){ref-type="fig"}; [Figure 4---figure supplement 2C](#fig4s2){ref-type="fig"}). These data provide another line of support that TOG array subunits form square assemblies in solution, and that they match the organization of a TOG square bound to four αβ-tubulins (termed wheels) as observed in the crystal structure ([Figure 2](#fig2){ref-type="fig"}) or these dissociated from αβ-tubulin leading to isolated square-shaped assemblies (termed squares) ([Figure 4](#fig4){ref-type="fig"}). In contrast, INT1:αβ-tubulin complexes did not form square assemblies, and particles exhibited either open flexible organization with many inter-connected 8 nm long inter-connected densities or 16 nm long short filaments. 2D-image classification showed either 16 nm curved filaments, two 8 nm densities at right angles, or isolated 8 nm densities. 2D-projection matching using low resolution filtered models for single TOG1-TOG2 subunit bound to two αβ-tubulins from a TOG square structure, polymerized TOG-αβ-tubulin complexes (see next section), or with individual TOG-αβ-tubulin complexes ([@bib11]) matched well to the three types of class averages ([Figure 4J](#fig4){ref-type="fig"}; [Figure 4---figure supplement 2D--F](#fig4s2){ref-type="fig"}). These data confirmed that these complexes were indeed either single TOG1-TOG2 subunits, with 90 degree pre-arranged and non-polymerized αβ-tubulin assemblies, TOG1-TOG2 bound to two polymerized αβ-tubulins assemblies, or disordered assemblies composed of isolated TOG-αβ-tubulin complexes. INT2-αβ-tubulin complexes showed similar pattern of class averages that matched similar models as INT1-αβ-tubulin complexes suggesting similarly dissociation of a single interface in the TOG square ([Figure 4K](#fig4){ref-type="fig"}; [Figure 4---figure supplement 2G--I](#fig4s2){ref-type="fig"}). While, INT1 +2 αβ-tubulin complexes showed only dissociated, flexibly connected necklaces of 8 nm densities of αβ-tubulin ([Figure 4L](#fig4){ref-type="fig"}). 2D-image classification of these particles and 2D-projection matching of these complexes showed that each 8 nm class averages matched 2D-projections of a TOG-bound αβ-tubulin ([Figure 4L](#fig4){ref-type="fig"}; [Figure 4---figure supplement 2J--K](#fig4s2){ref-type="fig"}). Our biochemical and negative stain-EM analyses suggest that wt-Alp14 dimer TOG arrays form square-shaped assemblies that match the organization observed in the TOG square crystal structure. Specific aspects of TOG square organization are clearly disrupted leading to the predicted defects in organization in the INT1, INT2, and INT1 +2 mutants without any effect on αβ-tubulin binding ([Figure 4J,K,L](#fig4){ref-type="fig"}). An interesting observation is that INT1 and INT2 mutants showed the propensity to form two polymerized αβ-tubulins filaments in some cases, suggesting that spontaneous in-solution αβ-tubulin polymerization occurs in the case of interface 1 and interface 2 destabilization ([Figure 4J,K](#fig4){ref-type="fig"}; [Figure 4---figure supplement 2E,H](#fig4s2){ref-type="fig"}). The dual inactivation of both TOG square interfaces in INT1 +2 resulted in dissociated TOG-αβ-tubulin complexes with a poor ability to form polymerize αβ-tubulins ([Figure 4L](#fig4){ref-type="fig"}; [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}).

X-ray structure of a polymerization complex: TOG1-TOG2 subunit unfurling promotes the concerted polymerization of two αβ-tubulin {#s2-6}
--------------------------------------------------------------------------------------------------------------------------------

The TOG square conformation shows how αβ-tubulins are recruited to TOG arrays but does not reveal how TOG arrays drive polymerization the recruited αβ-tubulins. We hypothesized that the TOG square structure may undergo a subsequent conformational change to promote polymerization of the recruited αβ-tubulins. To explore this transition, we created a biochemical approach to partially release αβ-tubulin from polymerization by relieving DRP inhibition of αβ-tubulin polymerization while they are bound to TOG arrays. We reasoned that a structural transition may occur more readily if DRP dissociates from β-tubulin in a crystallization setting. We developed a strategy to conditionally release αβ-tubulin from polymerization while being recruited into TOG arrays by using a weakened affinity DRP. We reasoned that the increased dissociation of DRP may allow complexes to form polymerized αβ-tubulin intermediates in steady state, as seen in the negative stain studies. To accomplish this, we removed the N-terminal ankyrin repeat of DRP (herein termed DRPΔN). We measured DRPΔN affinity using ITC, revealing a three-fold decrease in its αβ-tubulin-binding affinity as compared to DRP ([Figure 5A--B](#fig5){ref-type="fig"}). During purification, complexes of 1:2:2 sk-Alp14-monomer:αβ-tubulin:DRPΔN behaved similarly to those assembled with DRP on SEC ([Figure 5C](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). However, using crystallization conditions identical to those used to obtain the 4:4:2 TOG square conformation, we obtained crystals that exhibited a distinct rectangular morphology using sk-Alp14-monomer or sk-Alp14-dimer αβ-tubulin:DRPΔN complexes (see Materials and methods; [Figure 5---figure supplement 2A](#fig5s2){ref-type="fig"}). These crystals formed in the same space group (P2~1~) with distinct unit cell dimensions compared to the TOG square crystals ([Table 3](#table3){ref-type="table"}). These crystals exclusively formed only when DRPΔN was used with αβ-tubulin:sk-Alp14-monomer or -dimer complexes. We determined an X-ray structure to 3.2 Å resolution by molecular replacement using these crystals ([Figure 5---figure supplement 2B](#fig5s2){ref-type="fig"}). The structure revealed a novel assembly consisting of complexes with the stoichiometry of 1:2 sk-Alp14-monomer:αβ-tubulin and a single DRPΔN positioned on the top end of TOG2-bound β-tubulin (termed the 1:2:1 structure; [Figure 5E,F](#fig5){ref-type="fig"}; [Figure 5---figure supplement 2C--D](#fig5s2){ref-type="fig"}).

![X-ray structure of 1:2:1 TOG-array:αβ-tubulin:DRPΔN reveals unfurled TOG1-TOG2 array bound to two polymerized αβ-tubulins.\
(**A, B**) Top, schemes of DRP and DRPΔN binding to αβ-tubulin. DRP shifts the equilibrium toward dissociation from αβ-tubulin. Bottom, isothermal titration calorimetery studies reveal a three-fold decrease in affinity of DRPΔN binding to αβ-tubulin (461 nM) compared to DRP (149 nM). (**C, D**) Two schematic views of the TOG1-TOG2 αβ-tubulin complex transition from the TOG square (only half is shown) to the unfurled conformation upon DRPΔN dissociation. (**E, F**) Two orthogonal views of the 3.2 Å X-ray structure of 1:2:1 sk-Alp14 (red):αβ-tubulins (cyan and green):DRPΔN (yellow) complex, indicating a polymerized protofilament state. TOG2 and TOG1 are bound to the upper (α2β2) tubulin and lower (α1β1) tubulin, respectively.](elife-38922-fig5){#fig5}
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###### Intra and inter dimer curvature angles (°) of αβ-Tubulins observed in structures.

                                                   PDB ID    Intra dimer (α1β1) angle (°)   Inter dimer (β1α2) angle (°)
  ------------------------------------------------ --------- ------------------------------ ------------------------------
  Stathmin:RB3 complex with GTP                    3RYH      9.2                            10.3
  Stathmin:RB3 complex with GDP                    1SA0      13.0                           13.5
  αβ-tubulin:TOG1 complex with GTP                 4FFB      13                             \-
  αβ-Tubulin:TOG2 complex with GTP                 4U3J      13                             \-
  αβ-Tubulin:DRP complex with GDP                  4DRX      11.0                           \-
  Sk-Alp14-monomer:αβ-Tubulin:DRP wheel with GDP   Current   11.3                           \-
  Sk-Alp14-monomer:αβ-Tubulin:DRP-ΔN with GDP      Current   11.2                           16.4

\*Curvature of αβ-tubulin interface were determined as previously described by Rice and Brouhard 2015.

The refined 3.2 Å 1:2:1 X-ray structure revealed an extended conformation with two αβ-tubulins polymerized head-to-tail in a curved protofilament ([Figure 5E--F](#fig5){ref-type="fig"}). In this conformation, TOG1 and TOG2 did not form any interactions with each other and their adjoining linker became disordered ([Figure 5E,F](#fig5){ref-type="fig"}; [Figure 5---figure supplement 2C,D](#fig5s2){ref-type="fig"}). TOG1 and TOG2 were specifically bound to the lower and upper αβ-tubulins, respectively, of a highly curved protofilament. Only a single DRPΔN capped the TOG2-bound αβ-tubulin ([Figure 5E](#fig5){ref-type="fig"}). Compared to the TOG square, this 'unfurling' rearrangement required 68°-rotation and 32 Å translation of TOG2:αβ-tubulin hinging around interface 2 and TOG1-αβ-tubulin ([Figure 6A,B](#fig6){ref-type="fig"}). This transition promoted the concerted polymerization of TOG2:αβ-tubulin onto the plus-end of TOG1:αβ-tubulin, and consequently drove the dissociation of the second DRPΔN ([Figure 5C,D](#fig5){ref-type="fig"}). The two αβ-tubulin polymers in this complex were highly curved protofilaments (16.4° inter-dimer interface). This protofilament structure displayed \~3° more curvature than RB3/stathmin-αβ-tubulin curved protofilament structures ([Table 4](#table4){ref-type="table"}; [Figure 5---figure supplement 2E](#fig5s2){ref-type="fig"}) ([@bib31]). Comparison of the αβ-tubulin dimer structure (α2β2) within this 1:2:1 structure to the unpolymerized αβ-tubulin structure revealed that polymerization is associated with a 5° rotation and 10 Å translation in the T7 loop and H8 helix of the TOG2-bound α-tubulin, which engages TOG1-bound β-tubulin elements and the E-site-bound GDP nucleotide ([Figure 6C,D](#fig6){ref-type="fig"}). The latter conformational change likely stabilizes inter-dimer αβ-tubulin interfaces ([Figure 5D](#fig5){ref-type="fig"}), burying a 1650 Å inter-dimer interface ([Figure 5E,F](#fig5){ref-type="fig"}). This conformational change occurs at a site similar to those observed during the MT lattice GTP hydrolysis transition ([@bib10]). Thus, the 1:2:1 unfurled structure represents a concerted αβ-tubulin post-polymerization intermediate promoted by a single TOG1-TOG2 subunit prior to straightening the protofilament during polymerization at MT plus-ends.

![Unfurling the TOG array: TOG2 rotation around TOG1 promotes the bound αβ-tubulins to polymerize.\
(**A and B**) Conformational change of TOG2 (blue) around TOG1 (red) while each is bound to αβ-tubulin (green and cyan) from a corner subunit in the wheel assembly (left) and in the extended conformation (right). TOG2 rotates 32° and translates 68 Å upon release to drive αβ-tubulin polymerization into a protofilament. (**C**) Superimposing unpolymerized αβ-tubulin (yellow) onto the α2β2-tubulin shows a conformational change in α-tubulin at the inter-dimer interface induced by polymerization. (**D**) Close-up view of the polymerized inter-dimer interface. Unpolymerized αβ-tubulin (yellow) is superimposed onto α2β2 (grey) of 1:2:1 structure. The α2-tubulin T7 loop and H8 helix engage the β1-tubulin GDP nucleotide through a T7 loop 5 Å translation and H8 helix 5° rotation involving residues Asp245 (D245), Gly246 (G246), Ala247 (A247), and Leu248 (L248).](elife-38922-fig6){#fig6}

Modeling αβ-tubulin-bound TOG square and unfurled structure docking onto microtubule plus-ends {#s2-7}
----------------------------------------------------------------------------------------------

We next evaluated how X-ray structures of αβ-tubulin-bound TOG squares and unfurled TOG1-TOG2 αβ-tubulin assemblies can dock onto protofilament tips at MT plus-ends. Atomic models for these states were overlaid onto the terminal αβ-tubulins of curved GTP or GDP αβ-tubulin protofilament models ([Figure 7](#fig7){ref-type="fig"}). Attempts to dock the αβ-tubulin onto protofilament ends exposed at the MT minus-end caused substantial steric clashes, supporting the notion that TOG square states are completely incompatible with docking at MT minus-ends (data not shown). The four αβ-tubulin-bound TOG square assembly X-ray structure ([Figure 2](#fig2){ref-type="fig"}) was superimposed onto that of the terminal αβ-tubulin at protofilament ends in two docking orientations, either via the αβ-tubulins bound onto TOG1 or TOG2 ([Figure 7A,B](#fig7){ref-type="fig"}). We observed a slight steric surface overlap between the four αβ-tubulin-loaded TOG square and the curved protofilament when TOG1-αβ-tubulin was docked onto the β-tubulin at the protofilament plus-end ([Figure 7A](#fig7){ref-type="fig"}). This steric overlap was caused by overlap between αβ-tubulin-TOG2 from the second TOG1-TOG2 subunit in the TOG square with penultimate αβ-tubulin from the protofilament end ([Figure 7A](#fig7){ref-type="fig"}; [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). In contrast, we observed no steric contact when the TOG square was docked via αβ-tubulin-TOG2. In this orientation, the TOG1-αβ-tubulin from the second subunit was retracted by 10 Å from the penultimate αβ-tubulin in the protofilament in contrast to the TOG1-αβ-tubulin docking ([Figure 7B](#fig7){ref-type="fig"}). The differences between steric overlap of the TOG square with the protofilament in these two docking orientations were due to the asymmetric dimensions of the TOG square, caused by stagger between TOG1 and TOG2 domains at interface 1 compared to interface 2. These differences suggest that the destabilization of the TOG squares is more likely if TOG1-αβ-tubulin docks onto the protofilament plus-end in contrast to TOG2-αβ-tubulin docking. The unfurled 1:2 TOG1-TOG2:αβ-tubulin assembly can only be docked using TOG1-αβ-tubulin onto the protofilament plus-end and suggests that TOG2:αβ-tubulin is positioned the furthest away from the MT plus-end in this conformation. These models were used to assemble steps for a new MT polymerase model described in the discussion ([Figure 8](#fig8){ref-type="fig"}).

![Docking of atomic structures onto protofilament ends reveals the molecular details of unfurling.\
(**A**) Right, atomic model for four αβ-tubulin-bound TOG square X-ray structures ([Figure 2](#fig2){ref-type="fig"}) docked using αβ-tubulin bound to TOG1 at the terminal αβ-tubulin in a curved protofilament (PDB ID: 3RYH). Left, magnified view of the zone of steric contact between TOG2-αβ-tubulin in the second subunit and the penultimate αβ-tubulin of the protofilament below the polymerization site. (**B**) Right, atomic model for four αβ-tubulin-bound TOG square X-ray structure ([Figure 2](#fig2){ref-type="fig"}) docked using αβ-tubulin bound to TOG2 at the terminal αβ-tubulin in a curved protofilament (PDB ID: 3RYH). Left, magnified view of the zone shown in A between TOG1-αβ-tubulin in the second subunit and the penultimate αβ-tubulin of the protofilament. Details and overlay images are shown in [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}. (**C**) Docking the isolated TOG1-TOG2 two-αβ-tubulin assembly structure (extracted from the pseudo-dimer structure) onto the terminal αβ-tubulin of the curved protofilament. (**D**) Docking of the unfurled 1:2:1 unfurled assembly structure ([Figure 5](#fig5){ref-type="fig"}) to the curved protofilament revealing TOG1 to be positioned at the base of the new assembly while TOG2 is positioned at the outer end of the newly formed MT plus-end.](elife-38922-fig7){#fig7}

![A polarized unfurling model for TOG arrays as MT polymerases.\
An animation for this model is shown in [Video 1](#video1){ref-type="video"}. (**A**) Assembly of yeast MT polymerase dimeric TOG1-TOG2 subunits with four αβ-tubulins into an αβ-tubulin:TOG square. TOG squares diffuse along MT lattices modulated by tubulin C-termini interacting with SK-rich regions. (**B**) I. TOG square assemblies orient αβ-tubulins in wheel-shaped assemblies at MT plus-ends. II. These assemblies are destabilized upon TOG1-α-tubulin polymerizing onto the exposed β-tubulin at MT plus-ends, releasing TOG1-TOG2 subunits in corner conformations. III. The release of TOG2:αβ-tubulin allows free rotation around TOG1, driving two αβ-tubulins to polymerize. IV. TOG2 dissociates from the newly polymerized αβ-tubulin stabilizing protofilament at the plus-end while TOG1 anchors this αβ-tubulin onto the MT plus-end. V. Straightening of this new protofilament leads to the dissociation of TOG1. The rebinding of TOG1-TOG2 subunits to αβ-tubulins reforms the TOG square assembly and restarts the MT polymerase cycle. Atomic views for states I, II, and III are shown in [Figure 7](#fig7){ref-type="fig"}.](elife-38922-fig8){#fig8}

Discussion {#s3}
==========

A 'polarized unfurling' model for TOG arrays as MT polymerases {#s3-1}
--------------------------------------------------------------

Using the combination of structural and biochemical analyses, we propose a new model for TOG arrays as MT polymerases, which we term the 'polarized-unfurling' model. The model is summarized in [Figure 8](#fig8){ref-type="fig"} and animated in [Video 1](#video1){ref-type="video"}. This model is supported by X-ray structures of two states, negative EM studies of αβ-tubulin complexes of wt-Alp14-dimer and three interface inactivated Alp14 mutants, differences in affinities of TOG1 and TOG2 domains for αβ-tubulins, and described via docking of models at protofilament ends at each step ([Figure 7](#fig7){ref-type="fig"}). Our model suggests that TOG arrays form two separate conformations that together promote MT polymerase activity: an αβ-tubulin recruitment complex as denoted by the TOG square ([Figures 2](#fig2){ref-type="fig"}--[4](#fig4){ref-type="fig"}) and an unfurled MT plus-end polymerization complex denoted by the polymerized 1:2:1 TOG1-TOG2: αβ-tubulin X-ray structures ([Figure 5](#fig5){ref-type="fig"}). We have effectively trapped these states by regulating the polymerization propensities for αβ-tubulins using DRP affinity while bound to TOG arrays ([Figures 2](#fig2){ref-type="fig"} and [5](#fig5){ref-type="fig"}). We hypothesize that the association of the αβ-tubulin-bound TOG square onto the MT plus-ends, via β-tubulin binding, drives the destabilization of the TOG square state and promotes the concerted unfurling of the TOG-αβ-tubulins to polymerize into a new protofilament.

###### Animation of the mechanism of polarized unfurling for multiple TOG domains in a yeast MT polymerase.

This animation describes the 'polarized unfurling' mechanism for multiple TOG domains in promoting MT polymerization. Briefly, Yeast MT polymerases are dimers with each subunit including TOG1 and TOG2 domains separated by a linker and followed by unstructured SK-rich and coiled-coil domains. Each MT polymerase binds four αβ-tubulins forming TOG square assemblies, as shown in the ribbon diagram ([Figure 2](#fig2){ref-type="fig"}). TOG2 exchanges αβ-tubulin due to its rapid exchange rate, while TOG square assemblies diffuse along MT lattices loaded with αβ-tubulins at MT plus-ends, as visualized in [Figure 8](#fig8){ref-type="fig"}. Docking of TOG square assemblies via TOG2 αβ-tubulin does not destabilize the TOG square as described in [Figure 7](#fig7){ref-type="fig"}. The polymerization of αβ-tubulin-TOG1 destabilizes TOG square complexes at interface 1 due to steric contact as described in [Figure 7](#fig7){ref-type="fig"}. The destabilization of the TOG square releases TOG2, promoting polarized unfurling of two soluble αβ-tubulins into one curved protofilament at the MT plus-end, as visualized in [Figure 5](#fig5){ref-type="fig"}. The newly formed protofilament is further stabilized by the rapid dissociation of TOG2 from the outermost αβ-tubulin, and forms corners to enhance direct αβ-tubulin polymerization at the MT plus-end. Other MT polymerase molecules promote delivery of αβ-tubulin dimers via the 'polarized unfurling' mechanism at polymerizing MT plus-ends. Individual steps for this model are shown in [Figure 8](#fig8){ref-type="fig"}.

10.7554/eLife.38922.026

The polarized unfurling MT polymerase cycle {#s3-2}
-------------------------------------------

We envision the polarized unfurling model as follow: 1) Upon recruiting four soluble αβ-tubulins, dimeric TOG1-TOG2 arrays in proteins such Alp14 or Stu2, organize into compact TOG square assemblies in solution ([Figure 8A](#fig8){ref-type="fig"}). These assemblies place αβ-tubulins in close proximity with each other in a near head-to-tail polarized while inhibiting spontaneous polymerization. This 'ready-to-polymerize' orientation is due to the asymmetry in each TOG domain:αβ-tubulin interface and the unique head-to-tail assembly formed by two TOG1-TOG2 array subunits formed in the TOG square ([Figure 2](#fig2){ref-type="fig"}). 2) The αβ-tubulin-loaded TOG square assemblies diffuse along the MT lattice, mediated by an interaction of the SK-rich regions immediately C-terminal to TOG2, with acidic tubulin C-termini exposed on MT surfaces ([Figure 8A](#fig8){ref-type="fig"}). Proximity of the SK-rich region to the TOG array is essential for MT polymerase activity, and increasing its polypeptide distance causes MT polymerase defects ([@bib23]; [@bib9]; [@bib14]). 3) When the αβ-tubulin-loaded TOG squares reach the β-tubulins exposed at MT plus-end protofilament tips, α-tubulin of the TOG1- or TOG2-bound αβ-tubulin may polymerize with β-tubulin exposed at the MT plus-end tip ([Figure 8B--I](#fig8){ref-type="fig"}; [Figure 2B](#fig2){ref-type="fig"}). Although TOG squares may diffuse to MT minus-ends, docking onto α-tubulin at MT minus-ends is highly sterically inhibited, precluding the possibility of αβ-tubulin TOG square docking onto MT minus-ends. The αβ-tubulin docking of either TOG1 or TOG2 onto β-tubulin at MT plus-ends is likely to be random. However, two features of TOG domains favor TOG1-αβ-tubulin over TOG2 αβ-tubulin in docking onto MT plus-ends: A) TOG1 is more likely to be fully occupied by αβ-tubulin due to its slow exchange and high affinity compared to the rapid exchange of αβ-tubulin onto TOG2 ([Figure 1](#fig1){ref-type="fig"}). B) Steric overlap with MT protofilaments develops only if the TOG square docks via TOG1-αβ-tubulin but not if TOG2-αβ-tubulin docks ([Figure 7](#fig7){ref-type="fig"}; [Figure 8A--I and B--I](#fig8){ref-type="fig"}; [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). Thus, TOG squares docking to protofilament ends via TOG1-αβ-tubulin destabilizes the TOG square in contrast with TOG2:αβ-tubulin, which will not destabilize the TOG square at protofilament tips, leading to selection of TOG1 at the docking site (Figurer 8B-II). 4) The MT plus-end-induced TOG square destabilization likely triggers TOG square disassembly into two corner-shaped TOG1-TOG2 subunits at MT plus-ends. 5) Corner-like half-square TOG1-TOG2 subunit assemblies are then released which are likely unstable ([Figure 8B--II](#fig8){ref-type="fig"}), and interface 2 likely acts as a flexible hinge for TOG2 to freely rotate around TOG1, driven by Brownian motion. Reversible unfurling, or hinge rotation, promotes αβ-tubulin bound to TOG2 to polymerize catalytically onto the plus-end of the TOG1-bound αβ-tubulin ([Figure 8B--III](#fig8){ref-type="fig"}). The TOG1- and TOG2-bound αβ-tubulins polymerize in a single concerted unfurling event as seen in the polymerized TOG1-TOG2:αβ-tubulin X-ray structure ([Figure 5E,F](#fig5){ref-type="fig"}). This event effectively 'unfurls' a single curved protofilament from two αβ-tubulins pre-oriented onto an αβ-tubulin-loaded TOG1-TOG2 corner-like intermediate. No energy expenditure is required during unfurling, as reversible Brownian motion likely drives the unfurling activity. However, formation of the polymerized assembly intermediate is captured by the αβ-tubulin-αβ-tubulin inter-dimer polymerization interfaces, which become locked by the inter-dimer interface conformational change, as seen in in the polymerized state structure ([Figure 6A,B](#fig6){ref-type="fig"}). The αβ-tubulin inter-dimer interfaces (1650 Å^2^ surface area in a single interface) may compete with TOG square reformation (1930 Å^2^ in total for a TOG square). 6) A gradient in the αβ-tubulin exchange rates between TOG1 and TOG2 likely leads TOG2 to dissociate from its αβ-tubulin rapidly before TOG1 dissociates from its αβ-tubulin ([Figure 1](#fig1){ref-type="fig"}; [Figure 8A--VI](#fig8){ref-type="fig"}). The unfurled TOG1-TOG2 αβ-tubulin polymerized structure positions this affinity gradient spatially across lower and upper positions of the polymerized complex with respect to the MT plus-end ([Figure 6](#fig6){ref-type="fig"}). A tightly bound αβ-tubulin on TOG1 likely anchors the TOG array onto the MT plus-end while the rapidly exchanging αβ-tubulin promotes TOG2 release- an intermediate that promotes accelerated MT polymerase ([Figure 8B](#fig8){ref-type="fig"} IV). 10) Protofilament straightening during MT plus-end closure likely induces TOG1 dissociation from the lower αβ-tubulin of the newly polymerized protofilament as suggested previously by the 'catch and release' model ([@bib11]). The unbound TOG1-TOG2 arrays are finally released from the newly formed protofilament to reload with soluble αβ-tubulin from the cytoplasm. TOG arrays may then reform the TOG square assembly upon recruiting αβ-tubulins and restart the cycle, while the SK-rich region maintains contact with the polymerizing MT plus-end ([Figure 8B--V](#fig8){ref-type="fig"}) ([Video 1](#video1){ref-type="video"}).

Implications of 'polarized unfurling' {#s3-3}
-------------------------------------

The polarized unfurling model suggests that the MT polymerase activity of TOG arrays is due to three features: 1) pre-organization of αβ-tubulins onto the TOG square. promoted by interfaces 1 and 2. 2) MT plus-end-induced unfurling of TOG square via TOG1-αβ-tubulin induced destabilization ([Figure 7](#fig7){ref-type="fig"}). 3) Reversible unfurling driven by Brownian motion and the polymerization capacity of αβ-tubulins being recruited TOG1-TOG2 squares disassemble. The propensity of TOG1-TOG2 subunit head-to-tail self-assembly is strongly enhanced by C-terminal coiled-coil-dimerization or the presence of TOG3-TOG4 in metazoan TOG arrays such as XMAP215/ch-TOG proteins. The positive charge of the SK-rich region is essential to associate with the MT surface. The polarized unfurling model suggests that TOG1 and TOG2 serve specific roles in MT polymerase activity, TOG1 anchors the array and destabilizes the TOG square organization onto the MT plus-end, while TOG2 drives αβ-tubulin polymerization.

Comparison to other MT polymerase models {#s3-4}
----------------------------------------

Two other models were suggested for the functions of TOG arrays as MT polymerases. In these models, TOG1 and TOG2 domains were suggested to exhibit random or reversed orientations in the process of polymerizing αβ-tubulin, compared to the polarized unfurling model ([@bib12]; [@bib22]). Most recently, [@bib23] studied the roles of TOG1 and TOG2 in MT polymerase activity by generating All-TOG1 or All-TOG2 chimeras of the budding yeast Stu2 MT polymerase. This study concluded that any two TOG domains, regardless of identity, are required in a TOG array for MT polymerase activity. This observation agrees with the importance of two adjacent TOG domains being critical for forming a two αβ-tubulin polymerized complex. However, the study concluded that no higher order of organization, such as the TOG square observed here, was occurring since TOG domain identity did not influence MT polymerase activity. However, our TOG square assembly structure indicates that the critical 12-residue linker adjacent to TOG2 still remains in these All-TOG1 or All-TOG2 Stu2 constructs. Thus, our studies demonstrate that the chimeric constructs used in that study ([@bib23]) still retained a substantial TOG square assembly capacity, despite exchanging TOG1 for TOG2 domain sequences. These chimeric Stu2 proteins were not structurally characterized in that study, and thus their self-assembly properties using their modified TOG arrays remain unknown ([@bib23]).

Our cysteine mutagenesis, crosslinking/mass spectrometry, and negative stain EM studies indicate wt-Alp14-dimer forms TOG squares upon binding αβ-tubulin in solution ([Figures 3](#fig3){ref-type="fig"}--[4](#fig4){ref-type="fig"}). Biochemical and negative stain-EM suggest that interfaces 1 and two organize TOG square assemblies, and that their inactivation in the INT1, INT2, and INT1 +2 mutants results in specific loss of either interface 1 or interface 2 producing either single corner-like subunits bound to two orthogonally oriented αβ-tubulins, two spontaneously polymerized αβ-tubulins bound TOG1-TOG2 arrays (INT1 and INT2), or disorganized arrays composed of multiple TOG-αβ-tubulins (INT1 +2); however these defects did not influence the ability of TOG arrays to bind αβ-tubulins. Our data support that interfaces 1 and 2 pre-orient αβ-tubulins and suggest that spontaneous polymerization may occur if interface 1 or interface 2 become destabilized, supporting our model ([Figures 4](#fig4){ref-type="fig"}--[5](#fig5){ref-type="fig"}). The polarized unfurling model explains a well-documented observation that could not be previously rationalized. Fusion of protein masses such as GFP protein, but not short tags, onto the TOG1 N-terminus severely inactivates MT polymerases, exclusively activating their MT depolymerase activity without affecting αβ-tubulin binding ([@bib27]) and references herein). Our model shows that N-terminal fusions on TOG arrays strongly interfere with formation of a TOG square by forming blocks that sterically hinder interface 2 formation.

Comparison to other MT regulatory proteins with TOG arrays {#s3-5}
----------------------------------------------------------

Other conserved classes of MT regulatory TOG-like array proteins, such as CLASP and Crescerin/CHE-12, may form similar TOG square-like particles and modulate MT dynamics in related mechanisms. For instance, the *S. pombe* CLASP:αβ-tubulin complexes form wheel-like particles with similar dimensions and promote local MT rescue ([@bib8]; [@bib7]; [@bib20]). However, the high-resolution organization of these different TOG arrays remains to be determined at high resolution.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\   Designation                        Source                     Identifier                                                                                                        Additional\
  (species)\                                                                                                                                                                                      information
  or resource                                                                                                                                                                                     
  --------------- ---------------------------------- -------------------------- ----------------------------------------------------------------------------------------------------------------- ------------------
  Chemical\       Darpin D1\                         Invitrogen                 N/A                                                                                                               
  compound,\      (Synthetic DNA)                                                                                                                                                                 
  drug                                                                                                                                                                                            

  Chemical\       GTP                                Sigma                      G-8877                                                                                                            
  compound,\                                                                                                                                                                                      
  drug                                                                                                                                                                                            

  Chemical\       GDP                                Sigma                      G7127                                                                                                             
  compound,\                                                                                                                                                                                      
  drug                                                                                                                                                                                            

  Chemical\       Crystallization\                   TTP\                       4150--05600                                                                                                       
  compound,\      plates                             Labtech                                                                                                                                      
  drug                                                                                                                                                                                            

  Chemical\       Crystallization\                   Qiagen                     N/A                                                                                                               
  compound,\      sparse matrix\                                                                                                                                                                  
  drug            screens                                                                                                                                                                         

  Chemical\       PEG-8000                           Sigma                      1546605                                                                                                           
  compound,\                                                                                                                                                                                      
  drug                                                                                                                                                                                            

  Chemical\       PEG-2000                           Sigma                      8.21037                                                                                                           
  compound,\                                                                                                                                                                                      
  drug                                                                                                                                                                                            

  Chemical\       Copper(II)\                        Sigma                      C1297                                                                                                             
  compound,\      sulfate                                                                                                                                                                         
  drug                                                                                                                                                                                            

  Chemical\       1, 10-\                            Sigma                      131377                                                                                                            
  compound,\      phenanthroline                                                                                                                                                                  
  drug                                                                                                                                                                                            

  Chemical\       Trypsin                            Sigma                      T6567                                                                                                             
  compound,\                                                                                                                                                                                      
  drug                                                                                                                                                                                            

  Chemical\       Chymotrypsin                       Sigma                      C6423                                                                                                             
  compound,\                                                                                                                                                                                      
  drug                                                                                                                                                                                            

  Chemical\       Iodoacetamide                      Sigma                      I6125                                                                                                             
  compound,\                                                                                                                                                                                      
  drug                                                                                                                                                                                            

  Chemical\       4-Vinylpyridine                    Sigma                      V3204                                                                                                             
  compound,\                                                                                                                                                                                      
  drug                                                                                                                                                                                            

  Other           2:4:4 sk-\                         Protein\                   PDB: \#6MZF                                                                                                       Deposited Data\
                  Alp14-550:αβ-\                     Data Bank                                                                                                                                    (Atomic\
                  Tubulin:DRP                                                                                                                                                                     coordinates)

  Other           2:4:4\                             Protein\                   PDB: \#6MZE                                                                                                       Deposited\
                  sk-Alp14-550-\                     Data Bank                                                                                                                                    Data (Atomic\
                  SL:αβ-Tubulin:\                                                                                                                                                                 coordinates)
                  DRP                                                                                                                                                                             

  Other           1:2:1\                             Protein\                   PDB: \#6MZG                                                                                                       Deposited\
                  sk-Alp14-550:\                     Data Bank                                                                                                                                    Data (Atomic\
                  αβ-Tubulin:DRPΔN                                                                                                                                                                coordinates)

  Other           *Saccharomyces*\                   UniprotKB/\                P46675                                                                                                            Protein\
                  *cerevisiae* Stu2p                 Swiss-Prot                                                                                                                                   sequence

  Other           *Saccharomyces kluyveri*\          Lachancea kluyveri NRRL\   SKLU-Cont10078                                                                                                    Protein sequence
                  Stu2p or Alp14p                    Y-12651 chromosome                                                                                                                           

  Other           *Schizosaccharomyces*\             \                          O94534                                                                                                            Protein sequence
                  *pombe* Alp14p                     UniprotKB/\                                                                                                                                  
                                                     Swiss-Prot                                                                                                                                   

  Other           *Chaetomium*\                      UniprotKB/\                G0S3A7                                                                                                            Protein sequence
                  *thermophilum*\                    Swiss-Prot                                                                                                                                   
                  Stu2                                                                                                                                                                            

  Other           SoluBL21\                          AmsBio                     C700200                                                                                                           Model\
                  bacterial\                                                                                                                                                                      system\
                  expression\                                                                                                                                                                     (expression\
                  system                                                                                                                                                                          system)

  Recombinant\    pLIC*\_*V2*-Sc*\                   Current\                   N/A                                                                                                               Recombinant\
  DNA reagent     Stu2p-H~6~                         study                                                                                                                                        DNA constructs\
                                                                                                                                                                                                  Expressed\
                                                                                                                                                                                                  in bacterial\
                                                                                                                                                                                                  strains

  Recombinant\    pLIC*\_*V2*-Sk*\                   Current study              N/A                                                                                                               
  DNA reagent     Stu2p-H~6~                                                                                                                                                                      

  Recombinant\    pLIC_V2-Sc\                        [@bib5]                                                                                                                                      
  DNA reagent     Stu2-550-H~6~\                                                                                                                                                                  
                  (TOG1-TOG2\                                                                                                                                                                     
                  monomer)                                                                                                                                                                        

  Recombinant\    pLIC_V2-KL-Stu2\                   Current study              NA                                                                                                                
  DNA reagent     -monomer-H~6~\                                                                                                                                                                  
                  (residues 1--560)                                                                                                                                                               

  Recombinant\    pLIC_V2-CT\                        Current\                   NA                                                                                                                
  DNA reagent     Stu2-mon\                          study                                                                                                                                        
                  omer-H~6~\                                                                                                                                                                      
                  (residues 1--550)                                                                                                                                                               

  Recombinant\    pLIC_V2-SK\                        Current study              N/A                                                                                                               
  DNA reagent     Alp14-monomer-\                                                                                                                                                                 
                  H~6\ (residues\ 1-550)~                                                                                                                                                         

  Recombinant\    pLIC_V2-Sk\                        Current study              N/A                                                                                                               
  DNA reagent     Alp14-monomer\                                                                                                                                                                  
                  -SL-H~6~\                                                                                                                                                                       
                  (residues 1--550;\                                                                                                                                                              
                  linker\                                                                                                                                                                         
                  residues replaced\                                                                                                                                                              
                  KL sequence;\                                                                                                                                                                   
                  see Materials and methods)                                                                                                                                                      

  Recombinant\    pLIC_V2-\                          Current\                   N/A                                                                                                               
  DNA reagent     sk-wt-Alp14-\                      study                                                                                                                                        
                  dimer-H6\                                                                                                                                                                       
                  (residues 1--724)                                                                                                                                                               

  Recombinant\    pLIC_V2\                           Current\                   N/A                                                                                                               
  DNA reagent     -sk-Alp14-\                        study                                                                                                                                        
                  dimer- H~6~                                                                                                                                                                     

  Recombinant\    S180C\                                                                                                                                                                          
  DNA reagent     and L304C\                                                                                                                                                                      
                  (residues\                                                                                                                                                                      
                  1--724)                                                                                                                                                                         

  Recombinant\    pLIC_V2-\                          Current study              N/A                                                                                                               
  DNA reagent     sk-Alp14-\                                                                                                                                                                      
                  dimer- H~6~                                                                                                                                                                     

  Recombinant\    S41C and\                                                                                                                                                                       
  DNA reagent     E518C\                                                                                                                                                                          
                  (residues\                                                                                                                                                                      
                  1--724)                                                                                                                                                                         

  Recombinant\    pLIC_V2-wt\                        Current study              N/A                                                                                                               
  DNA reagent     -Alp14-dimer-\                                                                                                                                                                  
                  H~6~ (residues\                                                                                                                                                                 
                  1--690)                                                                                                                                                                         

  Recombinant\    pLIC_V2-TOG1M\                     Current study              N/A                                                                                                               
  DNA reagent     - H~6~ (residues\                                                                                                                                                               
                  1--690: Y23A\                                                                                                                                                                   
                  and R23A)                                                                                                                                                                       

  Recombinant\    pLIC_V2-TOG2M\                     Current study              N/A                                                                                                               
  DNA reagent     - H~6~ (residues\                                                                                                                                                               
                  1--690: Y300A\                                                                                                                                                                  
                  and K381A)                                                                                                                                                                      

  Recombinant\    pLIC_V2-INT1-H~6~\                 Current study              N/A                                                                                                               
  DNA reagent     (residues 1--690:\                                                                                                                                                              
                  L206A, L208A,\                                                                                                                                                                  
                  F275R D276A,\                                                                                                                                                                   
                  L277A, V278A,\                                                                                                                                                                  
                  K320L, R359A)                                                                                                                                                                   

  Recombinant\    pLIC_V2-INT2-H~6~\                 Current study              N/A                                                                                                               
  DNA reagent     (residues 1--690:\                                                                                                                                                              
                  L39D, S40A,\                                                                                                                                                                    
                  D42A, L437D,\                                                                                                                                                                   
                  S440A, E478A\                                                                                                                                                                   
                  and R479A)                                                                                                                                                                      

  Recombinant\    pLIC_V2\                           Current study              N/A                                                                                                               
  DNA reagent     -INT1 + 2 H~6~\                                                                                                                                                                 
                  (L206A, L208A,\                                                                                                                                                                 
                  F275R D276A,\                                                                                                                                                                   
                  L277A, V278A,\                                                                                                                                                                  
                  K320L, R359A\                                                                                                                                                                   
                  L39D, S40A,\                                                                                                                                                                    
                  D42A, L437D,\                                                                                                                                                                   
                  S440A, E478A\                                                                                                                                                                   
                  and R479A)                                                                                                                                                                      

  Recombinant\    pET303-H~6~-DRP                    Current\                   N/A                                                                                                               
  DNA reagent                                        study                                                                                                                                        

  Recombinant\    pLIC_V2-H~6~-DRPΔN                 Current\                   N/A                                                                                                               
  DNA reagent                                        study                                                                                                                                        

  Other           αβ-tubulin\                        Current\                   N/A                                                                                                               Native protein\
                  purified\                          study                                                                                                                                        purification
                  from porcine\                                                                                                                                                                   
                  brains                                                                                                                                                                          

  Other           [[α]{.ul}[β]{.ul}]{.ul}-tubulin\   [@bib16]                                                                                                                                     
                  purified from\                                                                                                                                                                  
                  porcine brains                                                                                                                                                                  

  Software,\      ASTRA V6.0                         Wyatt\                     [http://www.wyatt.](http://www.wyatt.com/products/software/astra.html)\                                           
  algorithm                                          Technology                 [com/products/](http://www.wyatt.com/products/software/astra.html)\                                               
                                                                                [software/astra.html](http://www.wyatt.com/products/software/astra.html)                                          

  Software,\      NanoAnalyze                        TA\                        <http://www.tainstruments.com/>                                                                                   
  algorithm                                          Instruments                                                                                                                                  

  Software,\      EMAN2                                                         <http://blake.bcm.edu/emanwiki/EMAN2>                                                                             
  algorithm                                                                                                                                                                                       

  Software,\      iMOSFLM                            [@bib13]                   <http://www.mrc-lmb.cam.ac.uk/harry/imosflm/ver721/quickguide.html>                                               
  algorithm\                                                                                                                                                                                      

  Software,\      PHASER                             [@bib40]                   <http://www.phaser.cimr.cam.ac.uk/index.php/>                                                                     
  algorithm                                                                                                                                                                                       

  Software,\      PHASER                             [@bib29]                   Phaser_Crystallographic\_\                                                                                        
  algorithm                                                                     Software                                                                                                          

  Software,\      PyMol                              Schrodinger, LLC           <http://www.pymol.org/>                                                                                           
  algorithm                                                                                                                                                                                       

  Software,\      UCSF-Chimera                       [@bib33]                   <https://www.cgl.ucsf.edu/chimera/>                                                                               
  algorithm                                                                                                                                                                                       

  Software,\      DM from CCP4 suite                 [@bib18]                   <http://www.ccp4.ac.uk/html/dmmulti.html>                                                                         
  algorithm                                                                                                                                                                                       

  Software,\      PHENIX                             [@bib1]                    <https://www.phenix-online.org>                                                                                   
  algorithm                                                                                                                                                                                       

  Software,\      anisotropy server                  [@bib37]                   <https://services.mbi.ucla.edu/anisoscale/>                                                                       
  algorithm                                                                                                                                                                                       

  Software,\      Phyre protein\                     [@bib25]                   [www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index](http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index)   
  algorithm       homology model                                                                                                                                                                  

  Software,\      Cr-yolo                            [@bib41]                   [http://sphire.](http://sphire.mpg.de/wiki/)\                                                                     
  algorithm                                                                     [mpg.de/wiki/](http://sphire.mpg.de/wiki/)                                                                        

  Software,\      Relion 2.2                         [@bib26]                   <https://www2.mrc-lmb.cam.ac.uk/relion/index.php>                                                                 
  algorithm                                                                                                                                                                                       

  Software,\      Cryosparc                          [@bib34]                   <https://cryosparc.com/>                                                                                          
  algorithm                                                                                                                                                                                       

  Software,\      MolProbity                         [@bib17]                   <http://molprobity.biochem.duke.edu>                                                                              
  algorithm                                                                                                                                                                                       

  Software,\      Coot                               [@bib21]                   <http://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/>                                                            
  algorithm                                                                                                                                                                                       

  Software,\      BLENDER\                           Blender\                   <https://www.blender.org/>                                                                                        
  algorithm       3D-animation                       foundation                                                                                                                                   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Protein expression and purification of Alp14 and sk-Alp14 proteins {#s4-1}
------------------------------------------------------------------

The coding regions for MT polymerases from *S. pombe* Alp14p (accession: BAA84527.1), *S. cerevisiae* Stu2p (accession: CAA97574.1), *Saccharomyces kluyveri* Alp14 or Stu2p (coding region identified in accession: SKLU-Cont10078), and *Chaetomium thermophilum* Stu2p (accession: XP_006692509) were inserted into bacterial expression vectors with a C-terminal His-tag. wt-Alp14-monomer (residues 1--510), wt-Alp14-dimer (residues 1--690), sk-Alp14-monomer (residues 1--550), sk-Alp14-dimer (residues 1--724), Sc-Stu2-dimer (residues 1--746), and Ct-Stu2-dimer (residues 1--719) constructs were generated, including with or without the SK-rich and coiled-coil dimerization regions. TOG1M and TOG2M mutants were generated via point mutagenesis of Y23A and R23A to inactivate TOG1 domains (TOG1M); and Y300A and K381A to inactivate TOG2 domains (TOG2M) ([@bib9]). The INT1 +2 mutant was generated via gene synthesis (Epoch Life Science) by introducing 15-residue mutations into the wt-Alp14-dimer sequence (L206A L208A F275R D276A L277A V278A K320L R359A L39D S40A D42A L437D S440A E478A R479A). The INT1 and INT2 mutants were generated by a PCR swapping strategy of INT1 +2 with wt-Alp14-dimer leading to INT1 with 8-residue mutations (L206A L208A F275R D276A L277A V278A K320L R359A) and INT2 with 7-residue mutations (L39D S40A D42A L437D S440A E478A R479A). Generally, constructs were transformed and expressed in BL21 bacterial strains using the T7 expression system, and were grown at 37°C and induced with 0.5 mM isopropyl thio-β-glycoside at 18°C overnight. Cells were centrifuged and then lysed using a microfluidizer (Avastin). Extracts were clarified via centrifugation at 18,000 x *g*. Proteins were purified using Ni-IDA (Macherey-Nagel) and/or ion exchange using Hitrap-SP or Hitrap-Q chromatography followed by size exclusion chromatography using a Superdex 200 (30/1000) column (GE Healthcare). DRP was synthesized (Gene Art, Life Technologies), inserted into bacterial expression vectors with a C-terminal 6 × His tag, and expressed as described above. Proteins were purified using Ni-NTA (Macherey-Nagel) followed by Hitrap Q ion exchange and followed by size exclusion chromatography as described above. Purified proteins were used immediately or frozen in liquid nitrogen for future use.

Biochemical analyses of Alp14:αβ-tubulin complexes {#s4-2}
--------------------------------------------------

Soluble porcine αβ-tubulin (10 μM or 20 μM) purified using two GTP-polymerization cycles at high ionic strength as previously described ([@bib16]) was mixed with 5 μM *S. kluyveri* (sk) or *S. pombe* wt-Alp14-monomer, wt-Alp14-dimer, TOG1M, TOG2M, INT1, INT2, or INT1 +2 mutant proteins and then diluted five-fold. To assess αβ-tubulin assembly, the protein mixtures were analyzed by mixing the proteins into 0.5 mL volumes and injecting them into a Superdex 200 (10/300) size exclusion chromatography (SEC) column equilibrated in 100 mM or 200 mM KCl binding buffer (50 mM HEPES \[pH 7.0\], 1 mM MgCl~2~, and 1 mM β-mercaptoethanol with 100 mM KCl or 200 mM KCl) using an AKTA purifier system (GE Healthcare). Elution fractions (0.5 mL) were collected and analyzed via sodium dodecyl sulfate polyacrylamide gel electrophoresis (Bio-Rad). The αβ-tubulin- and Alp14-containing bands were quantitated using densitometry to determine the amounts of bound and unbound αβ-tubulin in each SEC fraction. Molecular masses of wt-Alp14-monomer, wt-Alp14-dimer, TOG1M, TOG2M, INT1, INT2, and INT1 +2 proteins, αβ-tubulin, and their complexes were measured using SEC-coupled multi-angle light scattering (SEC-MALS). Complexes were separated on Superdex 200 Increase (10/300) columns (GE Healthcare) while measuring UV absorbance (Agilent 1100-Series HPLC), light scattering (Wyatt Technology miniDAWN TREOS), and refractive index (Wyatt Technology Optilab T-rEX). Concentration-weighted molecular masses for each peak were calculated using ASTRA six software (Wyatt Technology).

Isothermal titration calorimetery (ITC) was performed using a Nano-ITC (TA Instruments) to determine DRP and DRPΔN affinities for αβ-tubulin. Experiments were performed at 25°C. Soluble αβ-tubulin, DRP, and DRPΔN were diluted in 50 mM HEPES buffer, pH 7.3, 100 mM KCl, 1 mM MgCl~2~, and 50 μM GDP. The sample cell was filled with tubulin (20--40 μM) for every experiment. 135--250 μM of DRP or DRPΔN solutions were injected in volumes of 2 or 5 μL in a series of controlled doses into the sample cell. To determine TOG1 and TOG2 affinities for αβ-tubulin with DRP, proteins were diluted in 50 mM HEPES buffer, pH 7.3, 100 or 200 mM KCl, and 1 mM MgCl~2~. 100--250 μM of TOG1 or TOG2 solutions were injected in volumes of 2 or 5 μL in a series of controlled does into the sample cell containing 1:1 molar ratio of αβ-tubulin and DRP (20--40 μM). The results were analyzed with NanoAnalyze software (TA Instruments). Thermodynamic parameters were calculated using the standard thermodynamic equation: −*RT*ln*K~a~* = Δ*G* = Δ*H − T*Δ*S*, where Δ*G*, Δ*H*, and Δ*S* are the changes in free energy, enthalpy, and entropy of binding, respectively, *T* is the absolute temperature, and *R* is the gas constant (1.98 cal mol^−1^ K^−1^).

Crystallization of sk-Alp14:αβ-tubulin:DRP or drpδn complexes {#s4-3}
-------------------------------------------------------------

Complexes (200 μM) were screened for crystallization using commercial sparse matrix (Qiagen) or homemade screens in 96-well format using a Mosquito robot (TTP Labtech) via the hanging drop method. Cube-shaped crystals (5 μm on each edge) formed for sk-Alp14-monomer:αβ-tubulin:DRP complexes and grew over 4--7 days in 50 mM PIPES, 100 mM MgCl~2~ \[pH 7.0\], and 10--15% PEG-8000. Larger crystals were grown using micro-seeding ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). To obtain improved X-ray diffraction (see below), we used an sk-Alp14-monomer construct in which non-conserved 256--297 residue linkers were replaced by the shorter linker (including the residue sequence -AVPAQSDNNSTLQTDKDGDTLMGN-) from the *K. lactis* ortholog sequence (termed sk-Alp14-monomer-SL). Crystals were transferred to 50 mM PIPES, 100 mM MgCl~2~ \[pH 7.0\], 15% PEG-8000, and 25% glycerol for cryo-protection and flash frozen in liquid nitrogen.

Rectangular crystals of sk-Alp14-monomer:αβ-tubulin:DRPΔN complexes formed in 7--10 days under the same conditions described for cube-shaped TOG1-TOG2:αβ-tubulin:DRP crystals. These rectangular crystals exclusively formed using DRPΔN (did not form with DRP) and were obtained using a variety of constructs of monomeric as well as dimeric sk-Alp14-monomer ([Table 3](#table3){ref-type="table"}). Rectangular sk-Alp14-monomer:αβ-tubulin:DRPΔN crystals were treated for cryo-protection and flash frozen as described above.

X-ray diffraction and structure determination of sk-Alp14:αβ-tubulin assemblies {#s4-4}
-------------------------------------------------------------------------------

More than 100 sk-Alp14-monomer:αβ-tubulin:DRP crystals were screened for X-ray diffraction at the Argonne National Laboratory at the Advanced Photon Source microfocus 24-ID-C beamline. Anisotropic X-ray diffraction data were collected for the best cube-shaped crystals in the *P*2~1~ space group to 4.4 Å resolution in the best dimension, with unit cell dimensions *a* = 219 Å, *b* = 108 Å, and *c* = 283 Å ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). The sk-Alp14-monomer-SL:αβ-tubulin:DRP crystals showed improved diffraction and decreased anisotropy to 3.6 Å resolution in an identical *P*2~1~ unit cell ([Table 3](#table3){ref-type="table"}). X-ray diffraction data were indexed and scaled using iMOSFLM and treated for anisotropic diffraction using ellipsoidal truncation on the UCLA diffraction anisotropy server (services.mbi.ucla.edu/anisoscale). Phase information was determined using TOG1 (PDB ID:4FFB), TOG2 (PDB ID:4U3J), αβ-tubulin dimer, and DRP (PDB ID:4DRX) models using molecular replacement. Briefly, a truncated poly-alanine TOG domain including only its HEAT repeats was used in the molecular replacement rotation and translation search ([Figure 2---figure supplement 1B--C](#fig2s1){ref-type="fig"}). Eight αβ-tubulin and TOG domain solutions were identified based on the Log Likelihood Gain (LLG) values ([Figure 2---figure supplement 1B--C](#fig2s1){ref-type="fig"}). After eight cycles of density modification, the electron-density map revealed the TOG1 domains exclusively due to the unique C-terminal linker and vertical helix densities ([Figure 2---figure supplement 1D--E](#fig2s1){ref-type="fig"}). Density for eight DRP molecules was identified and built. DRP molecules interacted only with their cognate β-tubulin and did not form interfaces with α-tubulin from neighboring molecules ([Figure 2---figure supplement 1H](#fig2s1){ref-type="fig"}). Two 2:4:4 sk-Alp14-monomer:αβ-tubulin:DRP wheel-like models were built and subjected to cycles of rigid-body refinement and model building using the *S. kluyveri* ortholog sequence. Each asymmetric unit contained two wheel-like assemblies ([Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}). TOG1-TOG2 linker residues (residues 265--299 in native sk-Alp14 and residues 260--277 in sk-Alp14-SL) were not observed and were presumed to be disordered ([Figure 2---figure supplement 1F--H](#fig2s1){ref-type="fig"}). Density maps from each of the wheel-like models were averaged using non-crystallographic symmetry and then refined using the PHENIX program ([@bib1]). Initially, models were refined using non-crystallographic symmetry (16 fold NCS) restraints and strictly constrained coordinates with group B-factor schemes. In the final stage refinement, the strategy was switched to individual positional and isotropic B-factor with automatic weight optimization. A 4.4 Å sk-Alp14-monomer:αβ-tubulin:DRP structure and 3.6 Å sk-Alp14-monomer-SL:αβ-tubulin:DRP structure are reported; refinement statistics appear in [Table 3](#table3){ref-type="table"}.

Rectangular crystals formed from sk-Alp14-monomer:αβ-tubulin: DRPΔN diffracted to 3.2 Å resolution at the Argonne National Laboratory at the Advanced Photon Source microfocus APS 24-ID-C beamline. X-ray diffraction data were indexed in the *P*2~1~ space group with unique unit cell dimensions *a* = 115 Å, *b* = 194 Å, and *c* = 149 Å, with two complexes in each unit cell ([Table 3](#table3){ref-type="table"}). Phase information was determined using molecular replacement using the TOG1 and TOG2 domains and curved αβ-tubulin as search models ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). TOG1 and TOG2 domains were identified after cycles of density modification as described above. Four αβ-tubulins, four TOG domains, and two DRPΔN models were placed in the unit cell. The identity of TOG domains was determined using the conserved C-terminal linker and jutting helix in the TOG1 domain sequence. A single DRPΔN molecule was identified bound per two αβ-tubulin polymerized complex. Data from each extended assembly were combined using non-crystallographic symmetry (8-fold NCS) and were averaged and refined using the program PHENIX ([@bib1]) ([Table 3](#table3){ref-type="table"}). The individual positional coordinates and anisotropic B-factor were refined with automatic weight optimization in the final stage. A 3.2 Å resolution refined density map is presented in [Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}. Examining data quality of sk-Alp14-monomer:αβ-tubulin:DRP or sk-Alp14-monomer:αβ-tubulin:DRPΔN using PHENIX ([@bib1]) indicated that the diffraction data contained a small degree of pseudo*-*merohedral twinning. The twin fractions were adjusted during refinement of both models.

Cysteine mutagenesis and crosslinking analyses of sk-Alp14:αβ-tubulin assemblies {#s4-5}
--------------------------------------------------------------------------------

Based on the sk-Alp14-monomer:αβ-tubulin:DRP crystal structure, the *S. kluyveri* ortholog protein sk-Alp14, in its dimer form (residues 1--724), was used to generate crosslinking mutations. Interface 1 residues, which are in close proximity to each other, were mutated to cysteine: Ser180Cys (S180C) and Leu304Cys (L304C), which we termed S180C-L304C. Interface 2 residues, which are in close proximity to each other, were also mutated to cysteine: Ser41Cys (S41C) and Glu518Cys (E518C), which we termed S41C-E518C. The *S. kluyveri* ortholog dimer S180C-L304C mutant and S41C-E518C mutant proteins were purified as described above ([Figure 3E](#fig3){ref-type="fig"}). These constructs were used either directly or to make complexes with αβ-tubulin in a 2:4 (subunit:αβ-tubulin) molar ratio, as described in [Figure 1A](#fig1){ref-type="fig"}. These S180C-L304C and S41C E518C mutants or their αβ-tubulin complexes were then treated using 5 mM Cu-phenanthroline in 50 mM HEPES and 100 mM KCl, pH 7.0, for 5 min, then treated with 5 mM EDTA. These protein mixtures were subjected to SDS-PAGE under oxidizing conditions.

For LC/MS-MS mass spectrometry-based disulfide peptide mapping, S180C-L304C sk-Alp14 oxidized SDS-PAGE bands were subjected to in-gel proteolysis using either trypsin or chymotrypsin. Fragmented peptides were then purified and treated with 5 mM iodioacetamide, which covalently adds 57 Da in mass onto reduced cysteine-containing peptides, and does not affect cysteines locked in disulfides. The peptide mixture was then treated with 5 mM dithiothriatol to reduce disulfides and then treated with 5-vinyl chloride, which covalently adds 105 Da mass units onto newly reduced cysteine-containing peptides. LCMS/MS mass spectrometry was performed and the resulting peptides were analyzed. Peptides covering 90% of sk-Alp14 were identified as were the majority of cysteines. Only two peptides were identified with cysteine residues that included 105 Da mass units added as described in [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}.

Negative stain electron microscopy and image analysis of wt-Alp14 and TOG inactivated mutants in complex with αβ-tubulins {#s4-6}
-------------------------------------------------------------------------------------------------------------------------

SEC-purified αβ-tubulin complexes of wt-Alp14-dimer, INT1, INT2, and INT1 +2 at 100 mM KCl supplemented with glutaraldehyde 0.05% and 4:2 molar ratio were placed on glow discharged grids, blotted after 30--60 s, and then stained with multiple washes of 0.1% uranyl formate at pH 7.0. All the images for negatively stained specimens were grids were collected on an electron microscope (JEM-2100F; JEOL) equipped with a field emission gun using low-dose mode at 200 KeV paired with a DE-20 direct electron detector device (DDD) operating in integration mode. The images were then processed using neural networks picking using Cr-YOLO (Wagner et al, <https://doi.org/10.1101/356584>). The particle coordinates were imported into relion 2.2. Images were CTF corrected using CTFFIND4 (Grant et al,). Particles were manually screened and subjected to rounds of 2D-classification either in Relion 2.2 or using Cryosparc ([@bib34]; [@bib26]). For each data set, 2D-Class averages were grouped based on their conformation then compared to 30 Å resolution filtered models of 4:2 αβ-tubulin: TOG2-TOG2 in square conformation ([Figure 2](#fig2){ref-type="fig"}) and single TOG1-TOG2 subunit from the square conformation in the bent conformation bound to two non-polymerized αβ-tubulins ([Figure 6](#fig6){ref-type="fig"}), TOG1-TOG2 in the polymerized conformation ([Figure 5](#fig5){ref-type="fig"}) and a single TOG domain bound αβ-tubulin (PDB-ID:4FFD). The projection matching was performed using EMAN2 command e2classvsproj.py at 1--5 angular degree increments ([@bib39]).

Animating the MT polymerase 'polarized unfurling' mechanism {#s4-7}
-----------------------------------------------------------

The animation was created using BLENDER 3D-animation software (<http://blender.org>) as follows. Briefly, surface and ribbon models of PDB coordinates representing the structures were exported from UCSF-Chimera and imported into BLENDER, and then smoothed and optimized to generate animated models. Additional protein SK-rich regions and coiled-coil domains, whose structures are unknown, were thus modeled using sequence length and other information as guidance. The microtubule lattice was modeled based on the tubulin structure (PDB ID 3J6F). The dissociation of TOG1 and TOG2 domains from αβ-tubulins were simulated in the animation, based on biochemical studies described in [Figure 1](#fig1){ref-type="fig"} and its figure supplements.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Structural Basis of Tubulin Recruitment and Assembly by Tumor Overexpressed Gene domain array Microtubule Polymerases\" for consideration by *eLife*. Your article has been reviewed by Andrea Musacchio as the Senior Editor a Reviewing Editor, and three reviewers. The reviewers have opted to remain anonymous.

The same three reviewers evaluated also the accompanying manuscript, as you have suggested.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this first manuscript, crystal structures of two TOG domains from Alp14, bound to tubulin dimers, are presented to shed new light on how TOG domains stimulate microtubule polymerization. In one structure tubulin polymerization is blocked by the presence of a Darpin with high affinity for tubulin. This structure reveals a new and interesting square arrangement of 4 TOG domains (as found in an Alp14 dimer). The authors show by cross linking that this arrangement exists in solution. Using a Darpin with lower affinity the authors determine a structure in which the TOG domains have rearranged so that tubulin dimers are brought together ready for polymerization. Together with biochemical studies, which show a difference in affinity between TOG1 and TOG2 of Alp14, the authors put together a new model for how TOG domains catalyse microtubule growth.

The manuscript contains much that is new and interesting and it is a good candidate for *eLife*. The reviewers had however some major concerns that should be addressed.

Essential revisions:

1\) The negative stain EM data (Figure 4F-I) needs to be improved. The blobs shown in Figure 4F are similar to those observed with badly behaved samples in EM and there is currently no evidence they correspond to the Alp14 structure. The authors would need to be able to show 2D averages of the WT sample in order to use negative stain analysis and compare the averages to projections of the crystal structure. The particles in images in H and I are too close together. There is no evidence that the particles in the white boxes correspond to one Alp14 complex. The data would need to be collected at lower dilutions so individual particles are clear. It would also be important to provide 2D classification on these images.

2\) The evidence for the square form of the Alp14/tubulin complex playing a role in microtubule polymerization should be presented in this manuscript (particularly given that the reviewers did not support publication of the accompanying manuscript in *eLife* -- see the Decision regarding the accompanying manuscript). The authors should explain why a rather large number of mutations were introduced to disrupt the interfaces. The reviewers expected that a smaller number of mutations could have been sufficient and wondered whether effects other than disrupting the interfaces could lead to the defects in microtubule polymerisation.

3\) In parts the amount of the presented data are rather overwhelming particularly given that not all of the data are described. The presentation of these data needs to be improved. The data shown in Figure 1 and the related supplementary figures are only partly described. Therefore, this part of the manuscript requires hours of work to really understand which data support which claims. A better way to present these data could be to present in the main Figure 1: a graph summarising the most important MALS data for some complexes without Darpin (which ultimately are the strongest evidence for binding stoichiometries), Figure 1E and G; and present everything else in supplementary figures including a clear description/summary in their legends of what one sees in these figures.

4\) The presentation of the model in the Discussion section needs improvement. The current description of the model in Figure 8 gives the impression that the model is very speculative, probably because the description of the model is combined with the implications. The authors are encouraged to first describe the model in its entirety, then reiterate the supporting evidence for it, and only then discuss the implications.

5\) A recent publication (Geyer et al., 2018) provides data and a model that do not appear to be in agreement with the model proposed here. The authors should discuss these recently published findings and adjust claims as appropriate in the light of these new data.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Structural Basis of Tubulin Recruitment and Assembly by Microtubule Polymerases with Tumor Overexpressed Gene (TOG) Domain Arrays\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Andrea Musacchio (Senior Editor), a Reviewing Editor, and the two original reviewers.

The manuscript has been improved. Particularly the improved negative stain EM part has strengthened the manuscript and has satisfactorily addressed a major concern of the reviewers. All reviewers also welcome the other changes, particularly the editorial changes that have improved clarity of presentation in most parts. The reviewers accept the decision of the authors not to combine the biochemical data demonstrating functional importance of the interfaces involved in \'square assembly\' formation, with the structural data presented in this manuscript, although it would have strengthened the arguments made.

But there are some remaining issues that need to be addressed before acceptance.

Despite parts of the Discussion being clearer now, all reviewers agree that the Discussion can be considerably more concise. The discussion of the Cook et al. paper can be deleted, and the discussion of the Geyer et al., paper should be more balanced. The statement \"all-TOG1 or TOG2 chimeric constructs retained an MT polymerase activity level that was substantially lower than native Stu2\" seems to be an oversimplification, since Geyer et al. reported a 84% activity level for the TOG2-TOG2 construct, which is remarkably close to the wildtype level.

We therefore invite you submit a revised version of your manuscript with a more balanced and importantly substantially shorter discussion, focusing on the main points relevant to this study. We also ask to consider addressing previously stated minor concerns that have not been addressed yet and that could help to further improve clarity of presentation (e.g. size of amino acid labelling in Figure 7A).

10.7554/eLife.38922.036

Author response

> Essential revisions:
>
> 1\) The negative stain EM data (Figure 4F-I) needs to be improved. The blobs shown in Figure 4F are similar to those observed with badly behaved samples in EM and there is currently no evidence they correspond to the Alp14 structure. The authors would need to be able to show 2D averages of the WT sample in order to use negative stain analysis and compare the averages to projections of the crystal structure. The particles in images in H and I are too close together. There is no evidence that the particles in the white boxes correspond to one Alp14 complex. The data would need to be collected at lower dilutions so individual particles are clear. It would also be important to provide 2D classification on these images.
>
> We carried out negative electron microscopy, 2D classification, and projection-matching analyses to support the existence of the TOG square in wt-Alp14 and the nature of defects in TOG arrays in the INT1, INT2 and INT1+2 mutants in complex with tubulin, described in the revised figure 4 and its figure supplements. The TOG square organization is evident in 4:2 Alp14-ab-tubulin negative stain images. We have captured images and 2D-class averages for particles that match the conformation of TOG square assemblies with and without tubulin, which likely formed due to dissociation of ab-tubulins from Alp14 on the grids. The INT1, INT2:tubulin complexes displays a pre-polymerized (corner-bent-like) organization (as found for one subunit in a TOG square) with two non-polymerized ab-tubulins, or an unfurled post-polymerized TOG1-TOG2 bound to two ab-tubulin in a polymerized assembly, as well as isolated TOG1-tubulin complexes,.while INT1+2 shows only isolated TOG-ab-tubulin complexes. Taken together, these data show that the TOG square assembly forms in wt-Alp14, that the interfaces stabilize this conformation, and that the inactivation of these interfaces in INT1, INT2 and INT1+2 leads to specific forms of disassembled or polymerized TOG array bound ab-tubulin assemblies. The data also explain why INT1 subunits remain capable of unfurling activity.
>
> 2\) The evidence for the square form of the Alp14/tubulin complex playing a role in microtubule polymerization should be presented in this manuscript (particularly given that the reviewers did not support publication of the accompanying manuscript in eLife -- see the Decision regarding the accompanying manuscript). The authors should explain why a rather large number of mutations were introduced to disrupt the interfaces. The reviewers expected that a smaller number of mutations could have been sufficient and wondered whether effects other than disrupting the interfaces could lead to the defects in microtubule polymerisation.

We believe that the functional studies of inactivated square assembly interface mutants, currently presented by Cook et al., do not fit within the scope or questions posed in the Nithianantham et al., manuscript. We submitted a revision of the manuscript by Cook et al., for reconsideration by the reviewers at *eLife* (see above). Those data fit within the context of the other data described by Cook et al., which focus on the dynamic cycle of processive microtubule plus-end tracking and the microtubule polymerase cycle. The addition of three figures (and associated figure supplements) would distract from the structural studies that are the focus of the present investigation, and lengthen the current manuscript, which is already fairly long.

> 3\) In parts the amount of the presented data are rather overwhelming particularly given that not all of the data are described. The presentation of these data needs to be improved. The data shown in Figure 1 and the related supplementary figures are only partly described. Therefore, this part of the manuscript requires hours of work to really understand which data support which claims. A better way to present these data could be to present in the main Figure 1: a graph summarising the most important MALS data for some complexes without Darpin (which ultimately are the strongest evidence for binding stoichiometries), Figure 1E and G; and present everything else in supplementary figures including a clear description/summary in their legends of what one sees in these figures.

In the current manuscript, we revised the Results section to better describe the biochemical analyses of affinity and stoichiometry of tubulin binding to a variety of TOG array constructs. We have also streamlined the presentation of the experiments and conclusions in the Results section. We also revised the figure legends and supplementary figure legends to maximize clarity.

> 4\) The presentation of the model in the Discussion section needs improvement. The current description of the model in Figure 8 gives the impression that the model is very speculative, probably because the description of the model is combined with the implications. The authors are encouraged to first describe the model in its entirety, then reiterate the supporting evidence for it, and only then discuss the implications.

We have fully rewritten the Discussion section to present the steps of the microtubule polymerase model and the implications of the mechanism. We have also added a section describing the questions that arise from this model, motivating the studies described by Cook et al. These questions help clarify the importance of the dynamic studies of microtubule polymerases that are presented by Cook et al.

> 5\) A recent publication (Geyer et al., 2018) provides data and a model that do not appear to be in agreement with the model proposed here. The authors should discuss these recently published findings and adjust claims as appropriate in the light of these new data.

We compared our studies with those of Geyer et al., 2018 throughout both manuscripts. All-TOG1 and allTOG2 stu2 constructs showed a level of activity intermediate between those of single TOG1- or TOG2inactivated mutants and wt-Stu2 protein. Some observations made by Geyer et al. about the defects in TOG1- and TOG2-inactivated mutants and the role of dimerization are fairly consistent with data reported by Cook et al., (see our revised Cook et al. manuscript), while many other observations are not compatible. In Cook et al., we detected a dwell time (different from that reported by Geyer et al.,) for wt-Alp14 at MT plus-ends using stable fluorescent dyes. Generally, our two manuscripts focus on the higher-order organization of TOG arrays, while Geyer et al., focused on the interaction between a Ser/Lys positively charged region and the TOG arrays. Our data point to substantially different conclusions, some of which are not compatible with the conclusions of Geyer et al. We describe these issues and compare Geyer et al., in the revised Nithianantham et al., and Cook et al., manuscripts.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The manuscript has been improved. Particularly the improved negative stain EM part has strengthened the manuscript and has satisfactorily addressed a major concern of the reviewers. All reviewers also welcome the other changes, particularly the editorial changes that have improved clarity of presentation in most parts. The reviewers accept the decision of the authors not to combine the biochemical data demonstrating functional importance of the interfaces involved in \'square assembly\' formation, with the structural data presented in this manuscript, although it would have strengthened the arguments made.
>
> But there are some remaining issues that need to be addressed before acceptance.
>
> Despite parts of the Discussion section being clearer now, all reviewers agree that the Discussion section can be considerably more concise. The discussion of the Cook et al. paper can be deleted, and the discussion of the Geyer et al., paper should be more balanced. The statement \"all-TOG1 or TOG2 chimeric constructs retained an MT polymerase activity level that was substantially lower than native Stu2\" seems to be an oversimplification, since Geyer et al. reported a 84% activity level for the TOG2-TOG2 construct, which is remarkably close to the wildtype level.
>
> We therefore invite you submit a revised version of your manuscript with a more balanced and importantly substantially shorter discussion, focusing on the main points relevant to this study. We also ask to consider addressing previously stated minor concerns that have not been addressed yet and that could help to further improve clarity of presentation (e.g. size of amino acid labelling in Figure 7A).

We appreciate the positive comments regarding the revised version. In this further revised manuscript version we have made the requested changes to Figure 7 and the following editorial changes regarding the Discussion section:

1\) We present a significantly shortened and streamlined Discussion section.

2\) We have removed sections related to Cook et al.

3\) We have added the Title heading "Other MT polymerase models" where we added a revised more balanced our discussion of Geyer et al., 2018, addressing suggestions made by the reviewers.

4\) We have removed the Conclusion section.
